

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 APR 02 CAS Registry Number Crossover Limits Increased to
500,000 in Key STN Databases
NEWS 3 APR 02 PATDPAFULL: Application and priority number formats
enhanced
NEWS 4 APR 02 DWPI: New display format ALLSTR available
NEWS 5 APR 02 New Thesaurus Added to Derwent Databases for Smooth
Sailing through U.S. Patent Codes
NEWS 6 APR 02 EMBASE Adds Unique Records from MEDLINE, Expanding
Coverage back to 1948
NEWS 7 APR 07 CA/CAPLUS CLASS Display Streamlined with Removal of
Pre-IPC 8 Data Fields
NEWS 8 APR 07 50,000 World Traditional Medicine (WTM) Patents Now
Available in CAPLUS
NEWS 9 APR 07 MEDLINE Coverage Is Extended Back to 1947
NEWS 10 JUN 16 WPI First View (File WPIFV) will no longer be
available after July 30, 2010
NEWS 11 JUN 18 DWPI: New coverage - French Granted Patents
NEWS 12 JUN 18 CAS and FIZ Karlsruhe announce plans for a new
STN platform
NEWS 13 JUN 18 IPC codes have been added to the INSPEC backfile
(1969-2009)
NEWS 14 JUN 21 Removal of Pre-IPC 8 data fields streamline displays
in CA/CAPLUS, CASREACT, and MARPAT
NEWS 15 JUN 21 Access an additional 1.8 million records exclusively
enhanced with 1.9 million CAS Registry Numbers --
EMBASE Classic on STN
NEWS 16 JUN 28 Introducing "CAS Chemistry Research Report": 40 Years
of Biofuel Research Reveal China Now Atop U.S. in
Patenting and Commercialization of Bioethanol
NEWS 17 JUN 29 Enhanced Batch Search Options in DGENE, USGENE,
and PCTGEN
NEWS 18 JUL 19 Enhancement of citation information in INPADOC
databases provides new, more efficient competitor
analyses
NEWS 19 JUL 26 CAS coverage of global patent authorities has
expanded to 61 with the addition of Costa Rica

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:10:54 ON 09 AUG 2010

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 13:11:25 ON 09 AUG 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2010 HIGHEST RN 1235544-80-5

DICTIONARY FILE UPDATES: 8 AUG 2010 HIGHEST RN 1235544-80-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10519113rce1.str



```

chain nodes :
7  8  9  10  11  13  14  15  16  21
ring nodes :
1  2  3  4  5  6
chain bonds :
1-7  4-11  7-8  7-21  8-9  8-10  11-13  15-16
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-7  4-11  7-8  7-21  8-9  8-10  11-13  15-16
exact bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :
```

G1:H,Ak

G2:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS
11:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 21:CLASS

L1 STRUCTURE UPLOADED


=> d l1

L1 HAS NO ANSWERS

L1 STR

H 1

O²-Ak



G1 H, Ak

G2 [01], [02]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 13:12:03 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1127 TO ITERATE

100.0% PROCESSED 1127 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 20526 TO 24554

PROJECTED ANSWERS: 899 TO 1901


L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN

Absolute stereochemistry.


```
IN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-(1,1-dimethylethyl)-4-
hydroxy-
MF C16 H22 Cl2 N2 O2
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 50 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
 IN 3-Thiophenecarboxylic acid, 2-[[4-hydroxy-1-piperidinyl]carbonylamino]-
 4,5-dimethyl-, ethyl ester
 MF C15 H22 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 13:12:39 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 22088 TO ITERATE

100.0% PROCESSED 22088 ITERATIONS

1120 ANSWERS

SEARCH TIME: 00.00.01

L3 1120 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

192.03

192.25

FILE 'CAPLUS' ENTERED AT 13:12:44 ON 09 AUG 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2010 VOL 153 ISS 7
FILE LAST UPDATED: 8 Aug 2010 (20100808/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 154 L3

=> d ibib abs hitstr 100-154

L4 ANSWER 100 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:972057 CAPLUS
DOCUMENT NUMBER: 140:27765
TITLE: Preparation of piperidine derivatives as tachykinin receptor antagonists for treatment of frequent urination and urinary incontinence
INVENTOR(S): Ikeura, Yoshinori; Hashimoto, Tadatoshi; Tarui, Naoki; Shirai, Junya; Yamashita, Masayuki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 264 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101964	A1	20031211	WO 2003-JP6754	20030529
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2487688	A1	20031211	CA 2003-2487688	20030529
AU 2003241903	A1	20031219	AU 2003-241903	20030529
BR 2003011425	A	20050315	BR 2003-11425	20030529
EP 1553084	A1	20050713	EP 2003-733151	20030529
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

CN 1671662	A	20050921	CN 2003-818354	20030529
NZ 537330	A	20070427	NZ 2003-537330	20030529
JP 2004285038	A	20041014	JP 2003-154345	20030530
MX 2004011730	A	20050714	MX 2004-11730	20041125
US 20060167052	A1	20060727	US 2004-516252	20041129
US 7622487	B2	20091124		
ZA 2004010085	A	20060726	ZA 2004-10085	20041214
IN 2004KN01942	A	20061201	IN 2004-KN1942	20041216
NO 2004005701	A	20050216	NO 2004-5701	20041229

PRIORITY APPLN. INFO.:

		JP 2002-159338	A	20020531
		JP 2003-17885	A	20030127
		WO 2003-JP6754	W	20030529

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 140:27765
 GI



AB The title compds. I [wherein Ar = (un)substituted aryl, aralkyl, or heteroaryl; R¹ = H, acyl, (un)substituted hydrocarbonyl, or heterocyclyl; X = O or (un)substituted NH; Z = (un)substituted CH₂; ring A = (un)substituted piperidine; ring B = (un)substituted aryl; with exclusions] or prodrugs or salts thereof are prepared I have excellent tachykinin receptor antagonistic activity, and are useful for the treatment of frequent urination and urinary incontinence (no data). For example, the compound II•xHCl was prepared in a multi-step synthesis. II showed antagonistic activity with IC₅₀ of 0.025 nM against human substance P receptor. Formulations containing I as an active ingredient were also described.

IT 632344-35-5P 632345-55-2P 632345-57-4P
 632345-61-0P 632346-22-6P 632346-24-8P
 632346-28-2P 632346-69-1P 632346-71-5P
 632348-39-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperidine derivs. as tachykinin receptor antagonists for treatment of frequent urination and urinary incontinence)

RN 632344-35-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-N,3-diphenyl-, (3R,4S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 632345-55-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-N-cyclohexyl-3-(diphenylmethyl)-, (3R,4S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 632345-57-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-N-[4-(dimethylamino)phenyl]-3-(diphenylmethyl)-, (3R,4S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 632345-61-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-N-(3-cyanophenyl)-3-(diphenylmethyl)-, (3R,4S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 632346-22-6 CAPLUS

CN 1-Piperidinecarboxamide, 3-[bis(4-fluorophenyl)methyl]-4-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-N-cyclohexyl-, (3R,4S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 632346-24-8 CAPLUS

CN 1-Piperidinecarboxamide, 3-[bis(4-fluorophenyl)methyl]-4-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-N-[4-(dimethylamino)phenyl]-, (3R,4S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 632346-28-2 CAPLUS

CN 1-Piperidinecarboxamide, 3-[bis(4-fluorophenyl)methyl]-4-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-N-(3-cyanophenyl)-, (3R,4S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 632346-69-1 CAPLUS


CN 1-Piperidinecarboxamide, 3-[bis(4-fluorophenyl)methyl]-N-cyclohexyl-4-[[3-fluoro-5-(trifluoromethyl)phenyl]methoxy]-, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 632346-71-5 CAPLUS
 CN 1-Piperidinecarboxamide, 3-[bis(4-fluorophenyl)methyl]-N-[4-(dimethylamino)phenyl]-4-[[3-fluoro-5-(trifluoromethyl)phenyl]methoxy]-, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 632348-39-1 CAPLUS
 CN Benzoic acid, 2-[[[(3R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-(phenylmethyl)-1-piperidinyl]carbonyl]amino]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (33 CITINGS)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 101 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:931339 CAPLUS

DOCUMENT NUMBER: 140:5044

TITLE: Preparation of 3-aminoindazole derivatives as kinase inhibitors

INVENTOR(S): Martina, Katia; Brill, Wolfgang

PATENT ASSIGNEE(S): Pharmacia Italia S.P.A., Italy

SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097610	A1	20031127	WO 2003-EP4862	20030508
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2486101	A1	20031127	CA 2003-2486101	20030508
CA 2486101	C	20090707		
AU 2003227741	A1	20031202	AU 2003-227741	20030508
EP 1506176	A1	20050216	EP 2003-725180	20030508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011291	A	20050329	BR 2003-11291	20030508
JP 2005534635	T	20051117	JP 2004-505343	20030508
MX 2004011417	A	20050214	MX 2004-11417	20041117
US 20060106083	A1	20060518	US 2004-990866	20041117
US 7632854	B2	20091215		

PRIORITY APPLN. INFO.:

US 2002-381092P

P 20020517

WO 2003-EP4862


W 20030508

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S):

CASREACT 140:5044; MARPAT 140:5044

GI




AB The title compds. [I; R = halo, (un)substituted alkenyl, alkynyl, (hetero)aryl (attached to position 5 or 6 of the indazole ring); R1 = N:CHNR2R3, NHCOR4, NHCONR4R5, NHSO2R4, NHCO2R4; R2, R3 = H, alkyl; R4, R5 = H, alkyl, cycloalkyl, aryl, etc.] and pharmaceutically acceptable salts thereof together with pharmaceutical compns. comprising them, as well as combinatorial libraries of compds. I, are disclosed. Preparation of compds. I is described in nine synthetic examples. Thus, treating the resin bearing 6-(4-methoxyphenyl)-1H-indazol-3-amine (preparation given) with iso-Pr isocyanate followed by treatment with aqueous NH4OH, and cleavage from the resin afforded N-isopropyl-N'-[6-(4-methoxyphenyl)-1H-indazol-3-yl]urea. The compds. I or compns. may be useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity (no biol. data given) such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

IT 627858-40-6P 627858-50-8P 627858-62-2P
627858-74-6P 627858-86-0P 627858-99-5P
627859-10-3P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of 3-aminoindazole derivs. as kinase inhibitors)


RN 627858-40-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]-
(CA INDEX NAME)




RN 627858-50-8 CAPLUS


CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]-
(CA INDEX NAME)




RN 627858-62-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(3-thienyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-74-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(4-methylphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-86-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(2-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)



RN 627858-99-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(3-methylphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627859-10-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-4-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS
RECORD (13 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 102 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:892757 CAPLUS
DOCUMENT NUMBER: 139:381501
TITLE: Preparation of N-[thio(oxo)carbonylaminophenyl]uracils
as herbicides
INVENTOR(S): Schwarz, Hans-Georg; Andree, Roland; Hoischen,
Dorothee; Kluth, Joachim; Linker, Karl-Heinz;
Vidal-Ferran, Anton; Drewes, Mark Wilhelm; Dahmen,
Peter; Feucht, Dieter; Pontzen, Rolf
PATENT ASSIGNEE(S): Bayer CropScience AG, Germany
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093244	A1	20031113	WO 2003-EP4138	20030422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10219434	A1	20031120	DE 2002-10219434	20020502
CA 2484280	A1	20031113	CA 2003-2484280	20030422
AU 2003240459	A1	20031117	AU 2003-240459	20030422
AU 2003240459	B2	20081120		
EP 1503994	A1	20050209	EP 2003-729934	20030422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009872	A	20050419	BR 2003-9872	20030422
JP 2005535585	T	20051124	JP 2004-501383	20030422
MX 2004010863	A	20050214	MX 2004-10863	20041101
US 20060089262	A1	20060427	US 2005-514153	20051121
US 7521396	B2	20090421		
PRIORITY APPLN. INFO.:			DE 2002-10219434	A 20020502
			WO 2003-EP4138	W 20030422
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 139:381501				
GI				



AB Title compds. [I; Q = O, S; R1 = H, amino, (substituted) alkyl; R2 = carboxy, cyano, (thio)carbamoyl, (substituted) alkyl, alkoxy-carbonyl; R3 = H, halo, (halogenated) alkyl; R4 = H, cyano, (thio)carbamoyl, halo; R5 = cyano, (thio)carbamoyl, halo, (halogenated) alkyl, alkoxy; R6 = H, (substituted) alkyl, alkylcarbonyl, alkylsulfonyl, (halogenated) alkenyl, alkenylcarbonyl, etc.; R7 = (halogenated) alkoxy-carbonyl, alkoxy-carbonylalkylthio, hydroxyamino, cyanoalkylamino, (substituted) heterocyclyloxy, N-bonded (monocyclic) N-heterocyclyl, etc.], were prepared. Thus, a mixture of 3-(4-bromo-2-fluoro-5-isocyanatophenyl)-1-methyl-6-trifluoromethyl-1H-pyrimidin-2,4-one, piperidine-3-carboxylic acid Et ester, Et₃N, and MeCN was stirred for 15 h at room temperature to give 42% 1-[2-bromo-4-fluoro-5-(3-methyl-2,6-dioxo-4-trifluoromethyl-3,6-dihydro-2H-pyrimidin-1-yl)phenylcarbonyl]piperidine-3-carboxylic acid Et ester. I were said to show strong pre- and postemergent herbicidal activity and good crop tolerance.


IT 1026097-82-4 1026351-06-3 1027036-44-7
1027582-15-5

RL: PRPH (Prophetic)

(Preparation of N-[thio(oxo)carbonylaminophenyl]uracils as herbicides)


RN 1026097-82-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1026351-06-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1027036-44-7 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1027582-15-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT 623929-28-2P 623929-29-3P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [thio(oxo)carbonylaminophenyl]uracils as herbicides)
RN 623929-28-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)-pyrimidinyl]-4-fluorophenyl]-4-hydroxy- (CA INDEX NAME)



RN 623929-29-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-bromo-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)-pyrimidinyl]-4-fluorophenyl]-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 103 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:622568 CAPLUS
DOCUMENT NUMBER: 139:164710
TITLE: Preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity.

INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.;
Santella, Joseph B., III; Wacker, Dean A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA
SOURCE: U.S., 145 pp., Cont.-in-part of U.S. Ser. No. 465,286,
abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 108
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6605623	B1	20030812	US 2000-598821	20000621
US 6331541	B1	20011218	US 1999-465288	19991217
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
US 6605623	B1	20030812	US 2000-598821	20000621
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
CA 2413274	A1	20011227	CA 2001-2413274	20010620
WO 2001098269	A2	20011227	WO 2001-US19745	20010620
WO 2001098269	A3	20030710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098269	A2	20011227	WO 2001-XA19745	20010620
WO 2001098269	A3	20030710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098269	A2	20011227	WO 2001-XB19745	20010620
WO 2001098269	A3	20030710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			

	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098269	A2	20011227	WO 2001-XC19745	20010620	
WO 2001098269	A3	20030710			
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098269	A2	20011227	WO 2001-XD19745	20010620	
WO 2001098269	A3	20030710			
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098269	A2	20011227	WO 2001-XE19745	20010620	
WO 2001098269	A3	20030710			
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098269	A2	20011227	WO 2001-XF19745	20010620	
WO 2001098269	A3	20030710			
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098269	A2	20011227	WO 2001-XG19745	20010620	
WO 2001098269	A3	20030710			
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

		IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO	2001098269	A2	20011227	WO 2001-XH19745 20010620
WO	2001098269	A3	20030710	
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO	2001098269	A2	20011227	WO 2001-XI19745 20010620
WO	2001098269	A3	20030710	
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO	2001098269	A2	20011227	WO 2001-XJ19745 20010620
WO	2001098269	A3	20030710	
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO	2001098269	A2	20011227	WO 2001-XK19745 20010620
WO	2001098269	A3	20030710	
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO	2001098269	A2	20011227	WO 2001-XL19745 20010620
WO	2001098269	A3	20030710	
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 104 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:511323 CAPLUS
DOCUMENT NUMBER: 139:85337
TITLE: Preparation of carboxamidobenzothiazoles as A2A
adenosine receptor ligands
INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross,
Roger David; Riemer, Claus
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053961	A1	20030703	WO 2002-EP13769	20021205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030144288	A1	20030731	US 2002-307698	20021202
US 6734179	B2	20040511		
CA 2469876	A1	20030703	CA 2002-2469876	20021205
AU 2002356628	A1	20030709	AU 2002-356628	20021205
AU 2002356628	B2	20080417		
BR 2002014837	A	20040831	BR 2002-14837	20021205
EP 1456202	A1	20040915	EP 2002-805304	20021205
EP 1456202	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1602310	A	20050330	CN 2002-824848	20021205
CN 1286834	C	20061129		
JP 2005521647	T	20050721	JP 2003-554677	20021205
JP 4283116	B2	20090624		
AT 309242	T	20051115	AT 2002-805304	20021205
ES 2251628	T3	20060501	ES 2002-805304	20021205

RU 2293736	C2	20070220	RU 2004-121683	20021205
MX 2004005554	A	20040910	MX 2004-5554	20040608
PRIORITY APPLN. INFO.:			EP 2001-129273	A 20011212
			WO 2002-EP13769	W 20021205

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 139:85337
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = (un)substituted 3,6-dihydro-2H-pyran-4-yl, 5,6-dihydro-4H-pyran-3-yl, 5,6-dihydro-4H-pyran-2-yl, tetrahydropyranyl, cyclohex-1-enyl, cyclohexyl, 1,2,3,6-tetrahydropyridin-4-yl, or piperidin-4-yl; R2 = (un)substituted alkyl, piperidinyl, Ph, morpholinyl, or pyridinyl; and their pharmaceutically acceptable acid addition salts] were prepared as A2A adenosine receptor ligands. For example, II was prepared by Pd cross coupling of (7-iodo-4-methoxybenzothiazol-2-yl)carbamic acid Me ester with tributyl(3,6-dihydro-2H-pyran-4-yl)stannane at 100 °C for 16 h. I have a good affinity to the A2A-receptor and may be used in the treatment of diseases related to this receptor. For instance, all except one tested invention compds. showed binding to the human A2A adenosine receptor with pKi >8.0.

IT 554411-95-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (A2A receptor ligand; preparation of carboxamidobenzothiazoles as AA adenosine receptor ligands)

RN 554411-95-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(tetrahydro-2H-pyran-4-yl)-2-benzothiazolyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 105 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:511317 CAPLUS

DOCUMENT NUMBER: 139:85234

TITLE: Preparation of carboxamidobenzothiophenes as A2A adenosine receptor modulators

INVENTOR(S): Alanine, Alexander; Flohr, Alexander


PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 24 pp.
 CODEN: PIXXD2


DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053954	A1	20030703	WO 2002-EP13704	20021204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2469872	A1	20030703	CA 2002-2469872	20021204
AU 2002358597	A1	20030709	AU 2002-358597	20021204
AU 2002358597	B2	20071206		
EP 1456196	A1	20040915	EP 2002-792882	20021204
EP 1456196	B1	20090107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014936	A	20041214	BR 2002-14936	20021204
CN 1602309	A	20050330	CN 2002-824846	20021204
CN 1296368	C	20070124		
JP 2006500313	T	20060105	JP 2003-554670	20021204
JP 4197649	B2	20081217		
RU 2299882	C2	20070527	RU 2004-121682	20021204
AT 420082	T	20090115	AT 2002-792882	20021204
US 20030149030	A1	20030807	US 2002-315821	20021210
US 6730670	B2	20040504		
MX 2004005632	A	20041206	MX 2004-5632	20040610
PRIORITY APPLN. INFO.:			EP 2001-129269	A 20011212
			WO 2002-EP13704	W 20021204

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 GI



I




II


AB Title compds. I [wherein R = (un)substituted aryl, pyridinyl, NR₁R₂ = (un)substituted morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl; n = 0-2; and their pharmaceutically acceptable acid addition salts] were prepared as A₂A adenosine receptor modulators. For example, II was prepared by acylation of (4-methoxy-7-phenyl-benzo[b]thiophen-2-yl)-amine with 4-fluorobenzoyl chloride at 200 for 2 h. I have a good affinity to the A₂A-receptor and may be used in the treatment of diseases related to this

receptor. For instance, all the compds. I showed binding to the human A2A adenosine receptor with pKi > 6.4.

IT 554457-87-3P 554457-89-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(A2A adenosine receptor modulator; preparation of carboxamidobenzothiophenes as A2A adenosine receptor modulators)
RN 554457-87-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-(4-methoxy-7-phenylbenzo[b]thien-2-yl)- (CA INDEX NAME)



RN 554457-89-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-methoxy-N-(4-methoxy-7-phenylbenzo[b]thien-2-yl)- (CA INDEX NAME)




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 106 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:472390 CAPLUS
DOCUMENT NUMBER: 139:53026
TITLE: Preparation of ureidobenzothiazoles as adenosine receptor ligands
INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049741	A1	20030619	WO 2002-EP13761	20021205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
 UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20030149036	A1	20030807	US 2002-308338	20021203
US 6727247	B2	20040427		
CA 2469596	A1	20030619	CA 2002-2469596	20021205
AU 2002356626	A1	20030623	AU 2002-356626	20021205
AU 2002356626	B2	20071129		
BR 2002014825	A	20040914	BR 2002-14825	20021205
EP 1455792	A1	20040915	EP 2002-804578	20021205
EP 1455792	B1	20070418		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1602196	A	20050330	CN 2002-824654	20021205
JP 2005516006	T	20050602	JP 2003-550790	20021205
JP 4245483	B2	20090325		
AT 359792	T	20070515	AT 2002-804578	20021205
ES 2283652	T3	20071101	ES 2002-804578	20021205
RU 2311905	C2	20071210	RU 2004-121166	20021205
US 20040229893	A1	20041118	US 2003-691770	20031023
US 7019001	B2	20060328		
MX 2004005444	A	20041011	MX 2004-5444	20040604
PRIORITY APPLN. INFO.:				
			EP 2001-129228	A 20011210
			US 2002-308338	A3 20021203
			WO 2002-EP13761	W 20021205
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 139:53026				
GI				



I

AB Title compds. [I; R = alkoxy, halo; R₁, R₂ = H, alkyl, cycloalkyl, tetrahydropyran-4-yl; R₁R₂N = (substituted) 2-oxa-5-azabicyclo[2.2.1]heptyl, 3-endo-hydroxy-8-azabicyclo[3.2.1]octyl, 2-azabicyclo[2.2.2]octyl, 1-oxo-2,8-diazaspiro[4.5]decyl, 3-azaspiro[5.5]undecyl, 8-azaspiro[4.5]decyl, 1-oxa-8-azaspiro[4.5]decyl, 1,8,8-trimethyl-3-azabicyclo[3.2.1]octyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.2]octyl, 8-oxa-3-azabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.1]octyl, 2-azabicyclo[2.2.1]heptyl, 3-azabicyclo[3.2.1]octyl, piperazinyl, piperidin-1-yl; X = O, CH₂; n = 0-4], were prepared Thus, 4-methoxy-7-morpholin-4-ylbenzothiazol-2-ylamine in CH₂Cl₂ was treated with pyridine and Ph chloroformate and the resulting solution stirred for 45 min at ambient temperature;

(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane was added and the mixture stirred at ambient temperature for 15 min and at 40° for 2.5 h. to give (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxylic acid (4-methoxy-7-morpholin-4-ylbenzothiazol-2-yl)amide. This bound to human A2a receptors with pKi = 8.5.


IT 546093-51-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ureidobenzothiazoles as adenosine receptor ligands)

RN 546093-51-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-chloro-7-(1-piperidinyl)-2-benzothiazolyl]-4-hydroxy-4-[(4-methylphenyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 107 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:434303 CAPLUS

DOCUMENT NUMBER: 139:36445

TITLE: Preparation of 2-aminoquinolines as melanin concentrating hormone receptor (MCH-1R) antagonists.

INVENTOR(S): Devita, Robert J.; Chang, Lehua; Chaung, Danny; Hoang, Myle; Jiang, Jinlong; Lin, Peter; Sailer, Andreas W.; Young, Jonathan R.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 178 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045313	A2	20030605	WO 2002-US37556	20021122
WO 2003045313	A3	20030904		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

CA 2468015	A1	20030605	CA 2002-2468015	20021122
AU 2002352878	A1	20030610	AU 2002-352878	20021122
AU 2002352878	B2	20071122		
EP 1450801	A2	20040901	EP 2002-789837	20021122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005519876	T	20050707	JP 2003-546818	20021122
US 20050026915	A1	20050203	US 2004-496615	20040525
US 7084156	B2	20060801		
PRIORITY APPLN. INFO.:			US 2001-333581P	P 20011127
			WO 2002-US37556	W 20021122
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 139:36445				
GI				




AB Title compds. [I; R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkylalkyl, aralkyl, etc.; R1R2N = 4-11 membered (bridged) (substituted) heterocyclyl; R3, R4 = H, halo, (substituted) alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaralkyl, OR7, N(R7)2, cyano, etc.; R3R4 = atoms to form 5-7 membered (substituted) ring; R5 = H, halo, alkyl, perfluoroalkyl, OR7, N(R7)2; R6 = (CH2)nR7, (CH2)nCN, (CH2)nCO2R7, (CH2)nOR7, (CH2)nN(R7)2, etc.; R7 = H, alkyl, aryl, heteroaryl, cycloalkyl, aralkyl, aralkenyl, cycloalkylalkenyl, etc.; n = 0-5], were prepared for the treatment or prevention of obesity, eating disorders, osteoarthritis, cancer, AIDS wasting, cachexia, frailty, mental disorders, stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Thus, 2-piperidin-1-ylquinolin-6-amine and (2E)-3-(4-chlorophenyl)prop-2-enoyl chloride were stirred 3 h in HOAc to give (2E)-3-(4-chlorophenyl)-N-(2-piperidin-1-ylquinolin-6-yl)prop-2-enamide hydrochloride. I bound to MCH-1R receptors with IC50 = 0.1-10000 nM.

IT 539854-86-9P 539854-87-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compound; preparation of 2-aminoquinolines as melanin concentrating hormone receptor (MCH-1R) antagonists)


RN 539854-86-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[2-(2-azabicyclo[2.2.2]oct-2-yl)-6-quinolinyl]-4-hydroxy-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 539854-87-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[2-(2-azabicyclo[2.2.2]oct-2-yl)-6-quinolinyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 33 THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (42 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 108 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:282524 CAPLUS

DOCUMENT NUMBER: 138:304064

TITLE: Preparation of phenylurea derivatives as vanilloid receptor agonists

INVENTOR(S): Matsumoto, Takahiro; Yamamoto, Masataka; Nagabukuro, Hiroshi; Mochizuki, Manabu

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029199	A1	20030410	WO 2002-JP9995	20020927
WO 2003029199	A9	20030925		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002332331	A1	20030414	AU 2002-332331	20020927
EP 1437344	A1	20040714	EP 2002-768103	20020927

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2004339061 A 20041202 JP 2002-282514 20020927
 US 20040259912 A1 20041223 US 2004-489621 20040312
 PRIORITY APPLN. INFO.: JP 2001-300564 A 20010928
 WO 2002-JP9995 W 20020927
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 138:304064
 GI




AB The title compds. I [R1, R4 and R6 are each independently hydrogen, halogeno, or hydrocarbyl; R2 is hydrocarbyl or a heterocyclic group; R3 is hydrocarbyl, etc.; R5 is hydrocarbyl or a heterocyclic group (except quinolyl) and R51 is hydrogen or hydrocarbyl, or R5 and R51 together with the nitrogen atom adjacent thereto may form a ring; and R52 is hydrogen or hydrocarbyl] are prepared. I are useful for the treatment of pain, urinary incontinence, etc. In a tail flick test using mice, one compound of this invention showed a min. ED of 1 mg/kg.

IT 508216-23-7P 508216-25-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylurea derivs. as vanilloid receptor agonists)


RN 508216-23-7 CAPLUS

CN Benzoic acid, 2-(diphenylmethoxy)-5-[[4-(4-hydroxy-1-piperidinyl)carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 508216-25-9 CAPLUS

CN Benzoic acid, 5-[[[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]carbonyl]amino]-2-(diphenylmethoxy)-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 109 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:150534 CAPLUS
DOCUMENT NUMBER: 138:204946
TITLE: Preparation of N-ureidoalkylpiperidines as modulators
of CCR3 chemokine receptor activity for the prevention
of asthma and other allergic diseases
INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim,
Ui Tae; Wacker, Dean A.; Zheng, Changsheng
PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA
SOURCE: U.S., 126 pp., Cont.-in-part of U.S. Ser. No. 466,442.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 108
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6525069	B1	20030225	US 2000-597400	20000621
US 6331541	B1	20011218	US 1999-465288	19991217
US 6444686	B1	20020903	US 1999-466442	19991217
US 6525069	B1	20030225	US 2000-597400	20000621
US 6525069	B1	20030225	US 2000-597400	20000621
US 6525069	B1	20030225	US 2000-597400	20000621
US 6525069	B1	20030225	US 2000-597400	20000621
US 6525069	B1	20030225	US 2000-597400	20000621
US 6525069	B1	20030225	US 2000-597400	20000621
US 6525069	B1	20030225	US 2000-597400	20000621
US 6525069	B1	20030225	US 2000-597400	20000621
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
CA 2413421	A1	20011227	CA 2001-2413421	20010620
WO 2001098270	A2	20011227	WO 2001-US19752	20010620
WO 2001098270	A3	20020530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001098270	A2	20011227	WO 2001-XA19752	20010620
WO 2001098270	A3	20020530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098270	A2	20011227	WO 2001-XB19752 20010620
WO 2001098270	A3	20020530	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098270	A2	20011227	WO 2001-XC19752 20010620
WO 2001098270	A3	20020530	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098270	A2	20011227	WO 2001-XD19752 20010620
WO 2001098270	A3	20020530	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098270	A2	20011227	WO 2001-XE19752 20010620
WO 2001098270	A3	20020530	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098270	A2	20011227	WO 2001-XF19752 20010620
WO 2001098270	A3	20020530	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		

	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098270	A2	20011227	WO 2001-XG19752 20010620
WO 2001098270	A3	20020530	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098270	A2	20011227	WO 2001-XH19752 20010620
WO 2001098270	A3	20020530	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
EP 1294690	A2	20030326	EP 2001-950360 20010620
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
JP 2004516238	T	20040603	JP 2002-504226 20010620
US 20030013741	A1	20030116	US 2001-7172 20011023
US 6521592	B2	20030218	
US 20030114489	A1	20030619	US 2002-180869 20020626
US 6897234	B2	20050524	
US 20040002515	A1	20040101	US 2002-279416 20021024
US 6875776	B2	20050405	
US 20040006107	A1	20040108	US 2002-279231 20021024
US 6780857	B2	20040824	
US 20040034063	A1	20040219	US 2003-359443 20030206
US 6919368	B2	20050719	
US 20050096325	A1	20050505	US 2004-983367 20041108
US 20050192291	A1	20050901	US 2004-21042 20041223
PRIORITY APPLN. INFO.:			US 1998-112717P P 19981218
			US 1999-161221P P 19991022
			US 1999-466442 A2 19991217
			US 1999-161137P P 19991022
			US 1999-161184P P 19991022
			US 1999-161222P P 19991022
			US 1999-465287 A3 19991217
			US 1999-465288 A3 19991217
			US 1999-465948 A3 19991217
			US 2000-213208P P 20000621
			US 2000-597400 20000621
			WO 2001-US19752 W 20010620
			US 2002-180869 A1 20020626
			US 2002-279416 A1 20021024

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:204946
GI




AB Title compds. [I; M, Q = CH₂, CHR₅, CHR₁₃, CR₁₃R₁₃, CR₅R₁₃; J, K, L = CH₂, CHR₅, CHR₆, CR₆R₆, CR₅R₆; ≥1 of J, K, L contains R₅; Z = O, S, NR_{1a}, CHCN, CHNO₂, C(CN)₂; R_{1a} = H, alkyl, cycloalkyl, CN, NO₂, etc.; E = (substituted) C₃-6 carbocyclyl, methylenecarbocyclyl, ethylenecarbocyclyl, etc.; R₁, R₂ = H, alkyl, alkenyl, alkynyl; R₃ = (substituted) alkyl, alkenyl, alkynyl; R₄ = null, N-oxide, alkyl, alkenyl, alkynyl, cycloalkylalkyl, etc.; R₅ = (substituted) alkylenecarbocyclyl, alkyleneheterocyclyl; R₆ = alkyl, alkenyl, alkynyl, alkylcycloalkyl, perfluoroalkyl, hydroxyalkyl, mercaptoalkyl, aminoalkyl, CN, etc.; R₁₃ = alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, aminoalkyl, hydroxyalkyl, carboxyalkyl, mercaptoalkyl, acylaminoalkyl, (substituted) phenylalkyl, etc.], were prepared as CCR3 modulators (no data). Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) and 3-cyanophenyl isocyanate were stirred 30 min. in THF to give N-3-cyanophenyl-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea. [This abstract record is one of 8 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-ureidoalkylpiperidines as modulators of chemokine receptor activity)


RN 275810-67-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 110 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:695940 CAPLUS

DOCUMENT NUMBER: 137:216688

TITLE: Preparation of substituted sulfonylalkylcarboxamides as selective pde3b inhibitors and use of the same in therapy

INVENTOR(S): Snyder, Peter B.; Beaton, Graham; Rueter, Jaimie K.; Fanning, Dewey L.; Warren, Stephen D.; Hadida-Ruah, Sara S.

PATENT ASSIGNEE(S): Icos Corporation, USA

SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070469	A2	20020912	WO 2002-US5624	20020226
WO 2002070469	A3	20040304		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002247208	A1	20020919	AU 2002-247208	20020226
PRIORITY APPLN. INFO.:			US 2001-273497P	P 20010305
			WO 2002-US5624	W 20020226
OTHER SOURCE(S):	MARPAT 137:216688			
GI				



II

AB Title compds. I [A = (un)substituted aryl or heteroaryl; B = (un)substituted aryl or heteroaryl which may optionally be a fused bicyclic or polycyclic aromatic ring system; Y = CHR₄, CH₂CHR₄, CHR₄CH₂, NR_c, CO(CH₂)₁₋₂S(CH₂)₀₋₂, O(CH₂)₀₋₄, NR_cCO(CH₂)₀₋₂, and SO₂NHR_a(CH₂)₀₋₂; X = H, OH, alkoxy, cycloalkyl, CH(R_c)CH₂OH, NR_aR_b, bond between NR₂ and an atom of ring A or B, etc.; R₀ = halo, alkyl, alkenyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.; R₁ = alkyl or halo; R₂ = H, alkyl, aryl, heteroaryl, alkylenearyl, etc.; alternatively R₂ and X may together form an (un)substituted heterocycle; R₃ and R₄ independently = H, alkyl, aryl, heteroaryl, halo; R_a and R_b independently = H, alkyl, aryl, arylalkyl, etc.; or R_a and R_b together form a (un)substituted 5-6 membered ring optionally containing a heteroatom; R_c = H, aryl, heteroaryl, alkyl, cycloalkyl, etc.], and their pharmaceutically acceptable salts and solvates thereof, are prepared and disclosed as selective PDE3B inhibitors. Thus, II was prepared via Suzuki coupling of 3,4,5-trimethoxyboronic acid with 4-bromophenylmethanesulfonyl-N-hydroxyethyl acetamide. In vitro assays against phosphodiesterase 3b indicated compds. of the invention possess IC₅₀ values in the range of 0.01-8.5 μM.


IT 1106059-69-1

RL: PRPH (Prophetic)

(Preparation of substituted sulfonylalkylcarboxamides as selective pde3b inhibitors and use of the same in therapy)

RN 1106059-69-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4'-[[2-[(2-hydroxyethyl)amino]-2-oxoethyl]sulfonyl]methyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 111 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:504757 CAPLUS
 DOCUMENT NUMBER: 137:78855
 TITLE: Preparation of carbazoles as neuropeptide Y5 receptor ligands
 INVENTOR(S): Block, Michael Howard; Foote, Kevin Michael; Donald, Craig Samuel; Schofield, Paul
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051806	A1	20020704	WO 2001-GB5577	20011217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432008	A1	20020704	CA 2001-2432008	20011217
AU 2002217269	A1	20020708	AU 2002-217269	20011217
BR 2001016388	A	20030930	BR 2001-16388	20011217
EP 1358157	A1	20031105	EP 2001-272068	20011217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520324	T	20040708	JP 2002-552903	20011217
CN 1531527	A	20040922	CN 2001-822825	20011217
NZ 526623	A	20041126	NZ 2001-526623	20011217
ZA 2003004764	A	20040920	ZA 2003-4764	20030619
NO 2003002842	A	20030818	NO 2003-2842	20030620
MX 2003005648	A	20031006	MX 2003-5648	20030620
US 20040067999	A1	20040408	US 2003-450928	20031010
PRIORITY APPLN. INFO.:			GB 2000-31382	A 20001222
			GB 2001-21919	A 20010911
			WO 2001-GB5577	W 20011217


OTHER SOURCE(S): MARPAT 137:78855
 GI




AB The title compds. [I; R1 = alkyl, alkanoyl, alkylsulfonyl, etc.; R2, R3 = Me; or R2 and R3 together = (un)substituted (CH₂)₄ or (CH)₄; R4 = alkyl; R5 = CONR₉R₁₀, COR₉, COCOR₉; R6 = halo, CN, OH, etc.; R₉, R₁₀ = H, alkyl, alkoxy, etc.; or NR₉R₁₀ = (un)substituted heterocyclic ring; m = 0-2], useful as NPY 5 inhibitors in treating eating disorders, were prepared and

formulated. Thus, amidation of 4-morpholinecarbonyl chloride with 3-amino-2,4-dimethyl-9-isopropyl-9H-carbazole in the presence of Et₃N in DCM afforded I [R₁ = iso-Pr; R₂ and R₃ together = (CH)₄; R₄ = Me; R₅ = morpholinocarbonyl; R₆ = 2-Me; m = 1]. In general, compds. I possess an IC₅₀ in the range 0.0002 to 200 μM against NPY₅.


IT 439861-94-6P 439862-12-1P 439863-74-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of carbazoles as neuropeptide Y₅ receptor ligands)
 RN 439861-94-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[6-fluoro-4-methyl-9-(1-methylethyl)-9H-carbazol-3-yl]-4-hydroxy- (CA INDEX NAME)



RN 439862-12-1 CAPLUS
 CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methyl-9-(1-methylethyl)-9H-carbazol-3-yl]- (CA INDEX NAME)



RN 439863-74-8 CAPLUS
 CN 1-Piperidinecarboxamide, 4-hydroxy-N-[2-methyl-9-(1-methylethyl)-9H-carbazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 112 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:319364 CAPLUS
 DOCUMENT NUMBER: 137:125070
 TITLE: Study of the reactions of

2,2,6,6-tetramethyl-4-piperidinol with aromatic mono- and diisocyanates

AUTHOR(S): Bolcu, Constantin; Seiman, Corina

CORPORATE SOURCE: Facultatea de Chimie-Biologie-Geografie, Universitatea de Vest Timisoara, Timisoara, 1900, Rom.

SOURCE: Revista de Chimie (Bucharest, Romania) (2002), 53(2), 150-156

CODEN: RCBUAU; ISSN: 0034-7752

PUBLISHER: SYSCOM 18 SRL

DOCUMENT TYPE: Journal

LANGUAGE: Romanian

OTHER SOURCE(S): CASREACT 137:125070


AB The reactions of bifunctional photostabilizer 2,2,6,6-tetramethyl-4-piperidinol with Ph isocyanate, diphenylmethane 4,4'-diisocyanate, and toluene 2,4-diisocyanate were studied. Urethanes and allophanates are among possible products, which were analyzed by IR and UV-Vis spectroscopies, inverse phase HPLC, and thermal anal. The study of these reactions is useful in order to clear up some aspects concerning the way in which photostabilizers of this type bind with polyurethane mols. during the reactive photostabilization of the latter.

IT 444200-95-7P 444200-96-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(reactions of tetramethylpiperidinol with aromatic mono- and diisocyanates)


RN 444200-95-7 CAPLUS

CN 1-Piperidinecarboxamide, 2,2,6,6-tetramethyl-N-phenyl-4-
[[(phenylamino)carbonyl]oxy]- (CA INDEX NAME)



RN 444200-96-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-2,2,6,6-tetramethyl-N-phenyl- (CA INDEX NAME)



L4 ANSWER 113 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:185080 CAPLUS

DOCUMENT NUMBER: 136:247497


TITLE: Synthesis of piperidine derivatives as inhibitors of 2,3-oxidosqualene-lanosterol cyclase (OSC)

INVENTOR(S): Ackermann, Jean; Aebi, Johannes; Chucholowski, Alexander; Dehmlow, Henrietta; Morand, Olivier; Wallabaum, Sabine; Weller, Thomas


PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020483	A1	20020314	WO 2001-EP9941	20010829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020068753	A1	20020606	US 2001-939872	20010827
US 6964974	B2	20051115		
CA 2419588	A1	20020314	CA 2001-2419588	20010829
CA 2419588	C	20090922		
AU 2001085912	A	20020322	AU 2001-85912	20010829
EP 1317432	A1	20030611	EP 2001-965225	20010829
EP 1317432	B1	20080116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013752	A	20030729	BR 2001-13752	20010829
JP 2004508354	T	20040318	JP 2002-525105	20010829
CN 1231466	C	20051214	CN 2001-816941	20010829
AT 384047	T	20080215	AT 2001-965225	20010829
ES 2298253	T3	20080516	ES 2001-965225	20010829
ZA 2003001818	A	20040621	ZA 2003-1818	20030305
MX 2003002034	A	20030724	MX 2003-2034	20030307
PRIORITY APPLN. INFO.:			EP 2000-119677	A 20000908
			WO 2001-EP9941	W 20010829
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 136:247497				
GI				



I



II

AB Title compds. I [U = O, lone pair; V = O, CH₂, CH=CH, C.tplbond.C; m, n =

0-7 and $m + n = 0-7$; $W = \text{CO}, \text{COO}, \text{CONR1}, \text{CSO}, \text{CSNR1}, \text{SO2}, \text{or } \text{SO2NR1}$, with the proviso that : (a) V is not CH_2 if W is CO, (b) $m+n$ is 1 to 2 if V = CH_2 and W = SO_2 , (c) $m = n = 0$ if V is $\text{CH}=\text{CH}$ and W = CO or SO_2 , (d) $m = 1-7$ if V = O, (e) $n = 1-6$ or $m+n = 1-3$ if V = O and W is CO or SO_2 ; $\text{A1} = \text{H}, \text{alk(en)yl}$; $\text{A2} = \text{cycloalkyl}, \text{alkenyl}, \text{alkynyl}$; $\text{A3-4} = \text{H}, \text{alkyl}$; or A1-2 or A1 and A3 are bonded to each other to form a ring; $\text{A5} = \text{alk(en)yl}, \text{cycloalkyl}, (\text{hetero})$; $\text{R1} = \text{H}, \text{alkyl}$] were prepared For instance, 1-Boc-4-hydroxymethylpiperidine was alkylated with the O-trifluoromethanesulfonate ester of 3-bromo-1-propanol. This intermediate was deprotected (4N HCl, dioxane), acylated 4-bromobenzoyle chloride (CH_2Cl_2 , i-PrNEt₂) and reacted with allyl Me amine (acetone, K_2CO_3) to yield example compound [4-[3-(N-Allyl-N-methylamino)propoxy]piperidin-1-yl](4-bromophenyl)methanone (II) isolated as the fumarate salt. Compds. I inhibit 2,3-oxidosqualene-lanosterol cyclase (OSC) and are useful in the treatment of hypercholesterolemia, hyperlipemia, arteriosclerosis, etc.


IT 403799-26-8P, 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid N-(4-fluoro-3-trifluoromethylphenyl)amide
 403799-29-1P, 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid (2,4-difluorophenyl)amide 403799-31-5P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid (2,4-dimethoxyphenyl)amide 403799-33-7P,
 4-[6-(N-Allyl-N-methylamino)-hexyloxy]piperidine-1-carboxylic acid N-(4-fluorophenyl)amide 403799-35-9P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid N-(4-methoxyphenyl)amide 403799-37-1P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid N-(p-tolyl)amide 403799-39-3P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid (4-methoxy-2-methylphenyl)amide 403799-41-7P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid (2,4-dimethylphenyl)amide 403799-42-8P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid (3,4,5-trimethoxyphenyl)amide 403799-44-0P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid (3,4-dimethylphenyl)amide 403799-46-2P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid N-(4-acetylphenyl)amide 403799-48-4P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid N-(4-butylphenyl)amide 403799-50-8P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid (4-methylsulfanylphenyl)amide 403799-53-1P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid N-(4-isopropylphenyl)amide 403799-55-3P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid (3,4-dichlorophenyl)amide 403799-57-5P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid N-(4-bromophenyl)amide 403799-59-7P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid N-(naphthalen-2-yl)amide 403799-62-2P,
 4-[6-(N-Allyl-N-methylamino)hexyloxy]piperidine-1-carboxylic acid N-(naphthalen-1-yl)amide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; synthesis of piperidine derivs. as inhibitors of 2,3-oxidosqualene-lanosterol cyclase (OSC))


RN 403799-26-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-29-1 CAPLUS

CN 1-Piperidinecarboxamide, N-(2,4-difluorophenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-31-5 CAPLUS

CN 1-Piperidinecarboxamide, N-(2,4-dimethoxyphenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-33-7 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-35-9 CAPLUS


CN 1-Piperidinecarboxamide, N-(4-methoxyphenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-37-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-(4-methylphenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-39-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-(4-methoxy-2-methylphenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-41-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-(2,4-dimethylphenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)



RN 403799-42-8 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]-N-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 403799-44-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-(3,4-dimethylphenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-46-2 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-acetylphenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-48-4 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-butylphenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-50-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]-N-[4-(methylthio)phenyl]- (CA INDEX NAME)




RN 403799-53-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[4-(1-methylethyl)phenyl]-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-55-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)




RN 403799-57-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-(4-bromophenyl)-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]- (CA INDEX NAME)



RN 403799-59-7 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]-N-2-naphthalenyl- (CA INDEX NAME)



RN 403799-62-2 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]-N-1-naphthalenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 114 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:72044 CAPLUS

DOCUMENT NUMBER: 136:134675

TITLE: Preparation of heterocyclic amino alcohol beta-3 adrenergic receptor agonists

INVENTOR(S): Ashwell, Mark Anthony; Solvibile, William Ronald; Quagliato, Dominick Anthony; Molinari, Albert John

PATENT ASSIGNEE(S): American Home Products Corporation, USA

SOURCE: PCT Int. Appl., 208 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006229	A2	20020124	WO 2001-US22327	20010716
WO 2002006229	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020028832	A1	20020307	US 2001-903841	20010712
US 6451814	B2	20020917		
US 20030018045	A1	20030123	US 2002-189312	20020702
US 6605618	B2	20030812		

PRIORITY APPLN. INFO.: US 2000-218628P P 20000717

US 2001-903841 A1 20010712

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB This invention provides A-U-CH(OH)CH₂NHCH₂CH₂VC₆H₄WZ-p (1; Z = (1-Y-X-substituted piperidin-4-yl)) or a pharmaceutically acceptable salt


thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes. β 3-Adrenergic receptor EC50 and maximal response (IA; % activity compound/% activity isoproterenol) values are reported for .apprx.100 example compds., e.g. 0.032 μ M and 1.04 for 4-[4-[2-[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propylamino]ethyl]phenylamino]piperidine-1-carboxylic acid 2,6-difluorobenzylamide. In 1, A is (a) a 5-6 membered heterocyclic ring having 1-4 heteroatoms selected from O, N, and S, substituted with (R1)m; (b) a Ph ring substituted with (R1)m; (c) a naphthyl ring substituted with (R1)m; or (d) a Ph fused heterocycle selected from (R1)m-substituted 1,3-dihydro-2-oxo-2H-benzimidazol-4-yl, 1,3-benzodioxol-5-yl, 1,2,3,4-tetrahydro-2-oxoquinolin-5-yl, 1,2,3,4-tetrahydro-1-naphthylideneamino. U is -OCH2- or a bond; V is O or a bond; W is O, S(O)a, NR2, NC(O)R2; X = SO2, C(O), -(CH2)b, a bond, Ar; Y is -NR3R4, Het, Ar, alkyl of 1-8 C atoms, O(CH2)dR5. R1 is alkyl of 1-8 C atoms, -OR6, halogen, cyano, cycloalkyl of 3-8 C atoms, trifluoromethyl, CO2R6, -NR6R7, -C(O)NR6R7, -NHC(O)R6, -NR6C(O)NR8R8, -NHSO2R8, -S(O)aR6, -NO2, -O(CH2)eCO2R7, -OC(O)NR6R7, -O(CH2)fOR6, or a 5-6 membered heterocyclic ring containing 1 to 4 heteroatoms selected from O, S, and N. R2 is H, alkyl of 1-8 C atoms, or arylalkyl having 1-8 C atoms in the alkyl moiety; R3 and R4 are each, independently, H, alkyl of 1-8 C atoms, cycloalkyl of 3-8 C atoms, arylalkyl having 1-8 C atoms in the alkyl group, -(CH2)gR9, -(CH2)hCOR9, -(CH2)jCR10R11(CH2)jR9, or -(CH2)kCONR12R13; or R3 and R4 may be taken together together with the N to which they are attached to form a 3-7 membered saturated heterocycle, which may optionally contain 1-2 addnl. heteroatoms selected from O and S, and said heterocycle may optionally be substituted with R14. R5 is H; alkyl of 1-8 C atoms optionally substituted by 1-3 substituents selected from hydroxy, halogen and aryl; cycloalkyl of 1-8 C atoms; Ar or Het; R6, R7, and R8 are each, independently, H, or alkyl of 1-8 C atoms, or aryl of 6-10 C atoms, cycloalkyl of 3-8 C atoms, or arylalkyl having 1-8 C atoms in the alkyl moiety; R9 is H; alkyl optionally substituted with 1-3 substituents selected from hydroxy, halogen, and aryl; cycloalkyl of 3-8 C atoms; Ar, or Het; R10 and R11 are each, independently, H, alkyl, or aryl optionally substituted with alkyl of 1-8 C atoms or halogen; or R10 and R11 are taken together to form a spiro fused cycloalkyl ring of 3-8 C atoms. R12 and R13 are each, independently, H, alkyl of 1-8 C atoms, aryl optionally substituted with alkyl of 1-8 C atoms or halogen; or R12 and R13 are taken together with the N to which they are attached to form a 3-7 membered saturated heterocycle, which may optionally contain 1-2 addnl. heteroatoms selected from O and S, and said heterocycle may optionally be substituted with R14; R14 is CO2R15 or aryl optionally substituted with a 1-3 substituents selected from -OR15 and cycloalkyloxy of 3-8 C atoms; R15 is alkyl of 1-8 C atoms or arylalkyl having 1-8 C atoms in the alkyl moiety. Ar is an aromatic ring system containing 1-2 carbocyclic aromatic

rings

having 6-10 C atoms optionally mono, di, or trisubstituted with R16; Het is (a) a 5-6 membered heterocyclic ring having 1-4 heteroatoms selected from O, S, and N which may be optionally mono- or disubstituted with R16; or (b) a heterocyclic ring system optionally mono- or disubstituted by R16 containing a 5-6 membered heterocyclic ring fused to one or two carbocyclic or heterocyclic rings such that the heterocyclic ring system contains 1-4 heteroatoms selected from O, S, and N; R16 is aryl, halogen, alkyl of 1-8 C atoms, -OR17, cycloalkyl of 3-8 C atoms, trifluoromethyl, cyano, -CO2R17, -CONR17R18, -SO2NR17R18, -NR17OR18, -NR19CONR17R18, -NR17R18, -NR17COR18, -NO2, -O(CH2)pCO2R17, -OCONR17R18, -S(O)nR17, -O(CH2)qOR17, or a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from O, S and N. R17, R18, and R19 are each, independently, H, alkyl of 1-8 C

atoms, arylalkyl having 1-8 C atoms in the alkyl moiety, or aryl optionally mono, di, or trisubstituted with halogen, cyano, nitro, hydroxy, alkyl of 1-8 C atoms, or alkoxy of 1-8 C atoms; or when R17 and R18 are contained on a common N, R17 and R18 may be taken together with the N to which they are attached to form a 3-7 membered saturated heterocycle, which may optionally contain 1-2 addnl. heteroatoms selected from O and S. A = 0-2; b = 1-6; d = 0-3; e = 1-6; f = 1-6; g = 0-6; h = 0-6; j = 0-6; k = 0-6; m = 0-2; p = 1-6; q = 1-6. Methods of preparation are claimed, comprising (a) reacting AOCH₂-substituted oxirane or a protected form thereof in which a reactive substituent group is protected, with H₂NCH₂CH₂VC₆H₄WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 (U = -OCH₂-). (b) reacting A-substituted oxirane or a protected form thereof in which any reactive substituent group is protected, with H₂NCH₂CH₂VC₆H₄WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 wherein U represents a bond;. (c) reacting ACH(OPr)CH₂I, wherein Pr is a protecting group, with H₂NCH₂CH₂VC₆H₄WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 wherein U = -OCH₂-. (d) reacting ACH(OH)CH₂NH₂ or a protected form thereof in which any reactive substituent group is protected, with HO₂CCH₂VC₆H₄WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 wherein U = -OCH₂-. (e) removing any protecting group from 1 in which at least one substituent carries a protecting group to give 1; or (f) converting a basic compound 1 to a salt thereof by reaction with a pharmaceutically acceptable acid; or (g) converting 1 having one or more reactive substituent groups to a different 1; or (h) isolating an isomer of 1 from a mixture thereof. More than 100 example preps. are included.

IT 392628-39-6P, 4-Hydroxy-N-phenyl-1-piperidinecarboxamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of heterocyclic amino alc. beta-3 adrenergic receptor agonists)
 RN 392628-39-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-hydroxy-N-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 115 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:71877 CAPLUS
 DOCUMENT NUMBER: 136:134783
 TITLE: Preparation of piperazine(or piperidine)-1-carboxamides as CCR5 modulators
 INVENTOR(S): Bondinell, William E.; Neeb, Michael J.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent



LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005819	A1	20020124	WO 2001-US22529	20010713
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001080599	A	20020130	AU 2001-80599	20010713
EP 1313477	A1	20030528	EP 2001-958995	20010713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040038982	A1	20040226	US 2003-343880	20030205
PRIORITY APPLN. INFO.:			US 2000-218509P	P 20000715
			WO 2001-US22529	W 20010713

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:134783


GI




AB The title compds. [I; the basic N atom in moiety E may be optionally quaternized with alkyl or optionally present as the N-oxide; A = (un)substituted (hetero)aryl or (hetero)aryl fused to a saturated or partly unsatd. 5-7 membered ring; D = a bond, CO, SO₂, etc.; E1G = NC(R₂₆)₂, NC(R₂₆)₂C(R₂₆)₂, CR₂₇C(R₂₆)₂, C:CR₂₆; R₂₆ = H, alkyl; R₂₇ = H, CN, NO₂, etc.; R = H, alkyl, O; J = CO, SO₂; L = NR₃₀, O, C(R₃₀)₂; R₃₀ = H, alkyl; E = 3-(2-diisopropylamino)ethoxy-4-methoxyphenyl, etc.] which are modulators, agonists or antagonists, of the CCR5 receptor, and therefore are useful in the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases,

atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, were prepared Thus, treating 4-phenyl-1,2,3,6-tetrahydropyridine.HCl with triphosgene in the presence of Et3N in CH2Cl2 followed by addition of 3-(2-diisopropylamino)ethoxy-4-methoxyaniline afforded II. The compds. I showed CCR5 receptor modulator activity having IC50 values in the range of 0.0001-100 μ M. Furthermore, since CD8+ T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.

IT 391881-92-8P 391882-01-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of piperazine(or piperidine)-1-carboxamides as CCR5 modulators)
 RN 391881-92-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 391882-01-2 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[4-methoxy-3-[1-(1-methylethyl)-4-piperidinyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 116 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:935575 CAPLUS
 DOCUMENT NUMBER: 136:69739
 TITLE: Preparation of piperidinoalkylureas as chemokine receptor modulators
 INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Wacker, Dean A.; Zheng, Changsheng
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
 SOURCE: PCT Int. Appl., 333 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 108
 PATENT INFORMATION:

CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098270	A2	20011227	WO 2001-US19752	20010620
WO 2001098270	A3	20020530		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6525069	B1	20030225	US 2000-597400	20000621
CA 2413421	A1	20011227	CA 2001-2413421	20010620
WO 2001098270	A2	20011227	WO 2001-XA19752	20010620
WO 2001098270	A3	20020530		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098270	A2	20011227	WO 2001-XB19752	20010620
WO 2001098270	A3	20020530		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098270	A2	20011227	WO 2001-XC19752	20010620
WO 2001098270	A3	20020530		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098270	A2	20011227	WO 2001-XD19752	20010620
WO 2001098270	A3	20020530		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 2001098270 A2 20011227 WO 2001-XE19752 20010620
 WO 2001098270 A3 20020530
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 2001098270 A2 20011227 WO 2001-XF19752 20010620
 WO 2001098270 A3 20020530
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 2001098270 A2 20011227 WO 2001-XG19752 20010620
 WO 2001098270 A3 20020530
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 2001098270 A2 20011227 WO 2001-XH19752 20010620
 WO 2001098270 A3 20020530
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1294690 A2 20030326 EP 2001-950360 20010620
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004516238 T 20040603 JP 2002-504226 20010620
 PRIORITY APPLN. INFO.: US 2000-213208P P 20000621
 US 2000-597400 A 20000621
 US 1998-112717P P 19981218
 US 1999-161221P P 19991022
 US 1999-466442 A2 19991217
 WO 2001-US19752 W 20010620


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:69739


AB The title compds. were prepared as chemokine receptor modulators (no data).
 Thus, PhCH₂Z(CH₂)₃NHR (Z = piperidine-4,1-diyl) (I; R = H) (preparation given)
 was amidated by 3-(NC)C₆H₄NCO to give I [R = CONHC₆H₄(CN)-3]. [This

abstract record is one of 9 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinoalkylureas as chemokine receptor modulators)
RN 275810-67-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 117 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:935574 CAPLUS
DOCUMENT NUMBER: 136:69738
TITLE: Preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity.
INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B.; Wacker, Dean A.; Yao, Wenqing
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA; Bristol-Myers Squibb Pharmaceutical Co.
SOURCE: PCT Int. Appl., 446 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 108
PATENT INFORMATION:

CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098269	A2	20011227	WO 2001-US19745	20010620
WO 2001098269	A3	20030710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6605623	B1	20030812	US 2000-598821	20000621
CA 2413274	A1	20011227	CA 2001-2413274	20010620
WO 2001098269	A2	20011227	WO 2001-XA19745	20010620
WO 2001098269	A3	20030710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098269	A2	20011227	WO 2001-XB19745	20010620
WO 2001098269	A3	20030710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098269	A2	20011227	WO 2001-XC19745	20010620
WO 2001098269	A3	20030710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001098269	A2	20011227	WO 2001-XD19745	20010620
WO 2001098269	A3	20030710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			

		HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098269	A2	20011227	WO 2001-XE19745	20010620
WO 2001098269	A3	20030710		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098269	A2	20011227	WO 2001-XF19745	20010620
WO 2001098269	A3	20030710		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098269	A2	20011227	WO 2001-XG19745	20010620
WO 2001098269	A3	20030710		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098269	A2	20011227	WO 2001-XH19745	20010620
WO 2001098269	A3	20030710		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
WO 2001098269	A2	20011227	WO 2001-XI19745	20010620
WO 2001098269	A3	20030710		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		


SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GW, ML, MR, NE, SN, TD, TG
 WO 2001098269 A2 20011227 WO 2001-XJ19745 20010620
 WO 2001098269 A3 20030710
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GW, ML, MR, NE, SN, TD, TG
 WO 2001098269 A2 20011227 WO 2001-XK19745 20010620
 WO 2001098269 A3 20030710
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GW, ML, MR, NE, SN, TD, TG
 WO 2001098269 A2 20011227 WO 2001-XL19745 20010620
 WO 2001098269 A3 20030710
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GW, ML, MR, NE, SN, TD, TG
 WO 2001098269 A2 20011227 WO 2001-XM19745 20010620
 WO 2001098269 A3 20030710
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GW, ML, MR, NE, SN, TD, TG
 WO 2001098269 A2 20011227 WO 2001-XN19745 20010620
 WO 2001098269 A3 20030710
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GW, ML, MR, NE, SN, TD, TG
 EP 1363881 A2 20031126 EP 2001-950358 20010620
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI, CY, TR
 JP 2004517803 T 20040617 JP 2002-504225 20010620
 PRIORITY APPLN. INFO.: US 2000-213051P P 20000621
 US 2000-598821 A 20000621
 US 1998-112717P P 19981218
 US 1999-161243P P 19991022
 US 1999-465286 B2 19991217
 WO 2001-US19745 W 20010620

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:69738

GI




AB [Title compds. I; M = CH₂, CHR₅, CHR₁₃, CR₁₃R₁₃, CR₅R₁₃; Q = CH₂, CHR₅, CHR₁₃, CR₁₃R₁₃, CR₅R₁₃; J, L = CH₂, CHR₅, CHR₆, CR₆R₆, CR₅R₆; Z = O, S; M = CH₂, CHR₅, CHR₁₃, CR₁₃R₁₃, CR₅R₁₃; K = CHR₅, CR₅R₆; Z = O, S; E = (CHR₇)(CHR₉)v(CR₁₁R₁₂); R₁, R₂ = H, alkyl, alkenyl, alkynyl, (substituted) alkylcycloalkyl; R₂R₃ = atoms to form a (substituted) 5-7 membered ring; R₃, R₅ = (substituted) (alkyl)cycloalkyl, (alkyl)heterocyclyl; R₄ = null, O, alkyl, alkenyl, alkynyl, etc.; R₄ with R₇, R₉, or R₁₁ = atoms to form a 5-7 membered ring; R₇, R₉ = H; R₄R₇, R₄R₉ = (substituted) spirocyclyl; R₁₃ = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R₁₁R₁₂ = pyrrolidinyl, tetrahydrofuryl, piperidinyl, tetrahydropyranyl; v = 1, 2], were prepared as modulators of chemokine activity (no data). Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) in THF was treated with 3-cyanophenyl isocyanate to give N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea. [This abstract record is one of 15 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity)


RN 275810-67-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 118 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:935384 CAPLUS

DOCUMENT NUMBER: 136:69803

TITLE: Preparation of N-benzothiazol-2-yl amides having affinity toward the A2A adenosine receptor

INVENTOR(S): Alanine, Alexander; Flohr, Alexander; Miller, Aubry Kern; Norcross, Roger David; Riemer, Claus

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 160 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001097786	A2	20011227	WO 2001-EP6506	20010608
WO 2001097786	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2413086	A1	20011227	CA 2001-2413086	20010608
AU 2001081817	A	20020102	AU 2001-81817	20010608
EP 1303272	A2	20030423	EP 2001-960284	20010608
EP 1303272	B1	20080213		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012395	A	20030708	BR 2001-12395	20010608
HU 2003001315	A2	20030828	HU 2003-1315	20010608
HU 2003001315	A3	20071029		
JP 2003535887	T	20031202	JP 2002-503263	20010608
JP 3886897	B2	20070228		
RU 2251419	C2	20050510	RU 2003-100518	20010608
NZ 522928	A	20050527	NZ 2001-522928	20010608
AU 2001281817	B2	20051124	AU 2001-281817	20010608
CN 1234358	C	20060104	CN 2001-811534	20010608
EP 1797878	A2	20070620	EP 2007-3532	20010608
EP 1797878	A3	20100120		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, LT, LV, MK, RO, SI				
AT 385794	T	20080315	AT 2001-960284	20010608
PT 1303272	E	20080414	PT 2001-960284	20010608
ES 2299504	T3	20080601	ES 2001-960284	20010608
US 20020045615	A1	20020418	US 2001-881252	20010614
US 6521754	B2	20030218		
TW 309567	B	20090511	TW 2001-90114862	20010619
ZA 2002009730	A	20040301	ZA 2002-9730	20021129
US 20030125318	A1	20030703	US 2002-310508	20021205
US 6835732	B2	20041228		
HR 2002000962	A2	20050228	HR 2002-962	20021205
NO 2002005978	A	20021212	NO 2002-5978	20021212
NO 324635	B1	20071126		
IN 2002CN02070	A	20050225	IN 2002-CN2070	20021212
IN 211734	A1	20071228		
MX 2002012596	A	20030410	MX 2002-12596	20021217
US 20030176695	A1	20030918	US 2002-322272	20021218
US 6963000	B2	20051108		
HK 1058148	A1	20060324	HK 2004-100949	20040212
US 20050026906	A1	20050203	US 2004-930361	20040830
US 20060003986	A1	20060105	US 2005-219577	20050902
US 7317007	B2	20080108		
PH 1200700249	A	20090427	PH 2007-1200700249	20070626
NO 2007003465	A	20021212	NO 2007-3465	20070706
US 20080108809	A1	20080508	US 2007-930799	20071031
US 20080125419	A1	20080529	US 2007-930717	20071031
US 20100075959	A1	20100325	US 2009-628243	20091201


PRIORITY APPLN. INFO.:

EP 2000-113219	A	20000621
EP 2001-960284	A3	20010608
WO 2001-EP6506	W	20010608
US 2001-881252	A3	20010614
US 2002-322272	A3	20021218
US 2005-219577	A1	20050902
US 2007-930717	B1	20071031

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:69803

GI




AB The title compds. [I; R1 = H, alkyl, alkoxy, etc.; R2, R3 = H, halo, alkyl, alkoxy; R4 = H, alkyl, alkenyl, etc.; R = (un)substituted Ph, (CH2)n(5-6 membered (non)aromatic heterocyclyl, (CH2)n+1Ph, etc.; n = 0-4; X = O, S, H2)], useful for the treatment of diseases related to the adenosine receptor, were prepared Thus, reacting 2-amino-4-methoxy-7-phenylbenzothiazole with benzoyl chloride in pyridine afforded 69% I [R1 = OMe; R2, R3 = H; R4 = Ph; R = Ph; X = O]. Biol. data for compds. I were given.

IT 383867-98-9P, 4-Hydroxypiperidine-1-carboxylic acid
 [4-methoxy-7-(2-methylthiazol-4-yl)benzothiazol-2-yl]amide
 383867-99-0P, 4-Hydroxypiperidine-1-carboxylic acid
 [4-methoxy-7-(5-methylthien-2-yl)benzothiazol-2-yl]amide
 383868-93-7P 383869-09-8P 383869-25-8P
 383869-27-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)


RN 383867-98-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(2-methyl-4-thiazolyl)-2-benzothiazolyl]- (CA INDEX NAME)




RN 383867-99-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(5-methyl-2-thienyl)-2-benzothiazolyl]- (CA INDEX NAME)




RN 383868-93-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-cyclopropyl-4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (CA INDEX NAME)




RN 383869-09-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-phenyl- (CA INDEX NAME)




RN 383869-25-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (CA INDEX NAME)




RN 383869-27-0 CAPLUS
 CN 1-Piperidinecarboxamide, 4-methoxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 27 THERE ARE 27 CAPLUS RECORDS THAT CITE THIS RECORD (35 CITINGS)
 REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 119 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:769617 CAPLUS
 DOCUMENT NUMBER: 136:69990
 TITLE: Synthesis and evaluation of calystegine B2 analogues as glycosidase inhibitors
 AUTHOR(S): Garcia-Moreno, M. Isabel; Benito, Juan M.; Ortiz Mellet, Carmen; Garcia Fernandez, Jose M.
 CORPORATE SOURCE: Departamento de Quimica Organica Facultad de Quimica, Universidad de Sevilla, Seville, E-41071, Spain
 SOURCE: Journal of Organic Chemistry (2001), 66(23), 7604-7614
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:69990
 GI



I

AB A practical synthesis of polyhydroxylated 6-oxa-nor-tropanes, e.g. I, incorporating the essential structural features of calystegine B2 from 5-deoxy-5-thioureido and 5-ureido-L-idofuranose precursors is presented. The methodol. relies on the ability of pseudoamide-type nitrogen atoms (thiourea, urea, and carbamate) to undergo nucleophilic addition to the masked aldehyde group of the monosaccharide. The generated hemiaminal functionality may further undergo in situ intramol. glycosidation to give the bicyclic aminoacetal compds., the whole process being favored by the anomeric effect. A series of derivs. bearing different substituents at nitrogen has been prepared and screened against several glycosidases in comparison with xylonojirimycin-type piperidine analogs. Interestingly, strong and highly specific inhibition of bovine liver α -glucosidase was observed for 6-oxacalystegine B analogs incorporating aromatic pseudoaglyconic groups. On the basis of these data, a 1-aza-sugar inhibition mode is proposed for this family of glycomimetics.

IT 260544-78-3P 260544-79-4P


RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of calystegine B2 analogs via nucleophilic addition/glycosidation, their glucosidase and galactosidase inhibitory activity as glycomimetics)

RN 260544-78-3 CAPLUS

CN 1-Piperidinecarboxamide, 2,3,4,5-tetrahydroxy-N-phenyl-, (2R,3R,4S,5R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 260544-79-4 CAPLUS

CN 1-Piperidinecarboxamide, N- β -D-glucopyranosyl-2,3,4,5-tetrahydroxy-, (2R,3R,4S,5R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS
RECORD (23 CITINGS)
REFERENCE COUNT: 91 THERE ARE 91 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 120 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:521913 CAPLUS
DOCUMENT NUMBER: 135:107323
TITLE: Preparation of aminothiazole inhibitors of cyclin
dependent kinases
INVENTOR(S): Kim, Kyoung S.; Kimball, S. David; Cai, Zhen-wei;
Rawlins, David B.; Misra, Raj N.; Poss, Michael A.;
Webster, Kevin R.; Hunt, John T.; Han, Wen-ching
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: U.S., 164 pp., Cont.-in-part of U.S. 6,040,321.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6262096	B1	20010717	US 1999-464511	19991215
US 6040321	A	20000321	US 1998-176239	19981021
US 6214852	B1	20010410	US 2000-616629	20000726
US 6515004	B1	20030204	US 2000-727957	20001201
CA 2394538	A1	20010621	CA 2000-2394538	20001206
WO 2001044217	A1	20010621	WO 2000-US33037	20001206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000016420	A	20020820	BR 2000-16420	20001206
EP 1240153	A1	20020918	EP 2000-983935	20001206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003516981	T	20030520	JP 2001-544707	20001206
HU 2003001213	A2	20030828	HU 2003-1213	20001206
HU 2003001213	A3	20090330		
IL 149757	A	20080120	IL 2000-149757	20001206
CA 2394544	A1	20010621	CA 2000-2394544	20001207
CA 2394552	A1	20010621	CA 2000-2394552	20001207
WO 2001044241	A1	20010621	WO 2000-US33113	20001207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001044242	A1	20010621	WO 2000-US33501	20001207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000016424	A	20020820	BR 2000-16424 20001207
EP 1240165	A1	20020918	EP 2000-982481 20001207
EP 1240165	B1	20050504	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EP 1240166	A1	20020918	EP 2000-990204 20001207
EP 1240166	B1	20050216	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
SI 20975	A	20030228	SI 2000-20060 20001207
JP 2003516987	T	20030520	JP 2001-544732 20001207
EE 2002000306	A	20030616	EE 2002-306 20001207
HU 2003000974	A2	20030828	HU 2003-974 20001207
HU 2003000974	A3	20090330	
HU 2003001032	A2	20030828	HU 2003-1032 20001207
HU 2003001032	A3	20090330	
JP 2003525872	T	20030902	JP 2001-544731 20001207
NZ 519120	A	20040326	NZ 2000-519120 20001207
AU 774381	B2	20040624	AU 2001-19506 20001207
AT 289306	T	20050315	AT 2000-990204 20001207
AT 294800	T	20050515	AT 2000-982481 20001207
ES 2236034	T3	20050716	ES 2000-990204 20001207
PT 1240166	E	20050729	PT 2000-990204 20001207
PT 1240165	E	20050930	PT 2000-982481 20001207
ES 2241678	T3	20051101	ES 2000-982481 20001207
AU 783719	B2	20051201	AU 2001-27264 20001207
IL 149755	A	20090922	IL 2000-149755 20001207
EG 24168	A	20080910	EG 2000-1523 20001209
TW 265930	B	20061111	TW 2000-89126395 20001211
TW 273103	B	20070211	TW 2000-89126788 20001214
US 20010004639	A1	20010621	US 2000-746059 20001222
US 6392053	B2	20020521	
US 20010006976	A1	20010705	US 2000-746060 20001222
US 6414156	B2	20020702	
US 20020137778	A1	20020926	US 2001-839751 20010420
US 6521759	B2	20030218	
US 20020072609	A1	20020613	US 2002-67723 20020205
US 6613911	B2	20030902	
US 20020099217	A1	20020725	US 2002-100129 20020318
US 6639074	B2	20031028	
IN 2002MN00673	A	20050304	IN 2002-MN673 20020524
IN 2002MN00674	A	20050304	IN 2002-MN674 20020524
ZA 2002004349	A	20030901	ZA 2002-4349 20020530
ZA 2002004356	A	20031007	ZA 2002-4356 20020530
NO 2002002817	A	20020814	NO 2002-2817 20020613
NO 323726	B1	20070702	
MX 2002005870	A	20030128	MX 2002-5870 20020613
MX 2002005879	A	20030128	MX 2002-5879 20020613
NO 2002002864	A	20020813	NO 2002-2864 20020614
HK 1049661	A1	20051007	HK 2003-100935 20030207
US 20030216440	A1	20031120	US 2003-407779 20030404
US 20040063767	A1	20040401	US 2003-639272 20030812
US 6897321	B2	20050524	

PRIORITY APPLN. INFO.:



US 1997-65195P	P	19971112
US 1998-176239	A2	19981021
US 1999-464511	A2	19991215
US 2000-616627	A2	20000726
US 2000-616629	A	20000726
WO 2000-US33037	W	20001206

WO 2000-US33113	W	20001207
WO 2000-US33501	W	20001207
US 2000-746059	A3	20001222
US 2000-746060	A3	20001222
US 2002-67723	A3	20020205

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 135:107323

GI




AB The title compds. I [R1, R2 = H, F, alkyl; R3 = aryl, heteroaryl; R4 = alkyl, cycloalkyl, aryl, etc.; R5 = H, alkyl; m = 0-2; n = 1-3] were prepared I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example cancer, inflammation and arthritis. E.g., a multi-step synthesis of N-[5-[[[(5-ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]acetamide II which showed IC50 of < 50 μ M against cdc2/cyclin B1 kinase, against cdk2/cyclin E kinase, and against cdk4/cyclin D1 kinase, was given.

IT 224437-73-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminothiazole inhibitors of cyclin dependent kinases)

RN 224437-73-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-[[[(5-ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-4-hydroxy- (CA INDEX NAME)





OS.CITING REF COUNT: 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)
 REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 121 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:228848 CAPLUS
 DOCUMENT NUMBER: 134:266103
 TITLE: Preparation of N-tetrahydronaphthalenyl carboxamides as melanin concentrating hormone antagonists
 INVENTOR(S): Kato, Kaneyoshi; Terauchi, Jun; Mori, Masaaki; Suzuki, Nobuhiro; Shimomura, Yukio; Takekawa, Shiro; Ishihara, Yuji
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 363 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021577	A2	20010329	WO 2000-JP6375	20000919
WO 2001021577	A3	20011004		
W:	AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2386474	A1	20010329	CA 2000-2386474	20000919
EP 1218336	A2	20020703	EP 2000-961075	20000919
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2002003370	A	20020109	JP 2000-290357	20000920
US 7115750	B1	20061003	US 2002-88771	20020319
US 20070173498	A1	20070726	US 2005-224744	20050912
PRIORITY APPLN. INFO.:			JP 1999-266298	A 19990920
			JP 1999-357889	A 19991216
			JP 2000-126272	A 20000420
			WO 2000-JP6375	W 20000919
			US 2002-88771	A3 20020319

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 134:266103
GI



AB The title compds. [I; Ar¹ = (un)substituted cyclic group; X = a spacer having a main chain of 1-6 atoms; Y = a bond, a spacer having a main chain of 1-6 atoms; Ar = (un)substituted monocyclic aromatic ring which may be condensed with a 4-8 membered non-aromatic ring; R¹, R² = H, a hydrocarbon group which may have substituents; NR¹R² may form a (un)substituted nitrogen-containing hetero ring; R² may form a spiro ring together with Ar; R², together with the adjacent nitrogen atom and Y, may form a (un)substituted nitrogen-containing hetero ring] and their salts, useful as agents for preventing or treating obesity, were prepared and formulated. Thus, reacting 6-amino-2-[(dimethylamino)methyl]tetralin with 4-(4-methoxyphenyl)benzoic acid in the presence of HOBt, WSCD, Et₃N and DMAP in DMF afforded the carboxamide II which showed IC₅₀ of 40 nM in GTPγS binding assay.


IT 331757-27-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-tetrahydronaphthalenyl carboxamides as melanin concentrating hormone antagonists)

RN 331757-27-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4-hydroxy- (CA INDEX NAME)




OS.CITING REF COUNT: 50 THERE ARE 50 CAPLUS RECORDS THAT CITE THIS RECORD (64 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 122 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:756674 CAPLUS
 DOCUMENT NUMBER: 133:309842
 TITLE: Preparation of carbazole derivatives for treatment of
 neuropeptide Y-related diseases
 INVENTOR(S): Nishikawa, Naoyuki; Sugai, Masaharu; Aoki, Kozo;
 Suzuki, Makoto; Ikegawa, Akihiko; Takahashi, Kazunobu;
 Ohsawa, Fukuichi; Takei, Naomi; Kakui, Nobukazu;
 Tanaka, Jiro; Tabata, Yuji; Asai, Kenji
 PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan; et al.
 SOURCE: PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063171	A1	20001026	WO 2000-JP2573	20000420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1184373 A1 20020306 EP 2000-917373 20000420 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO US 6713473 B1 20040330 US 2002-926355 20020219 PRIORITY APPLN. INFO.: JP 1999-111698 A 19990420 JP 1999-200228 A 19990714 WO 2000-JP2573 W 20000420				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 133:309842
 GI




I

AB The title compds. I [A is a five- to seven-membered hydrocarbon ring; L is NR₃CO, CONR₃, or the like (wherein R₃ is hydrogen, lower alkyl, or lower acyl); M is an alkylene group (wherein the carbon atoms constituting the carbon chain may be each replaced by nitrogen, oxygen, or the like); X is S, O, NR₄, NR₅CO, a single bond, or the like (wherein R₄ and R₅ are each hydrogen, lower alkyl, or the like); Y is alkyl, aryl, amino, an aromatic heterocyclic group, or the like; R₁ is lower alkyl, lower alkenyl, lower alkynyl, or lower acyl; and R₂₁, R₂₂ and R₂₃ are each hydrogen,

hydroxyl, lower alkyl, or the like] are prepared I are ligands for neuropeptide Y receptors. I are useful in the treatment of neuropeptide Y-related diseases, such as hyperphagia, etc. In in vitro tests for inhibition of binding to the Y5 receptors, the title compds. at 10 μ M gave 67% to 100% inhibition.

IT 302556-67-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of carbazole derivs. for treatment of neuropeptide Y-related diseases)
 RN 302556-67-8 CAPLUS
 CN 1-Piperidinecarboxamide, 4-hydroxy-N-[2,3,4,9-tetrahydro-9-(1-methylethyl)-1H-carbazol-6-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
 REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 123 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:420964 CAPLUS
 DOCUMENT NUMBER: 133:43445
 TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
 INVENTOR(S): Ko, Soo S.; Duncia, John V. K.; Santella, Joseph B., III; Wacker, Dean A.; Kim, Ui Tae
 PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
 SOURCE: PCT Int. Appl., 351 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 108
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035454	A1	20000622	WO 1999-US30336	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2348923	A1	20000622	CA 1999-2348923	19991217
WO 2000035454	A1	20000622	WO 1999-XA30336	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035454	A1	20000622	WO 1999-XB30336	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ,				

[illegible]

	PT, SE				
WO 2000035454	A1	20000622	WO 1999-XM30336	19991217	
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035454	A1	20000622	WO 1999-XN30336	19991217	
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035454	A1	20000622	WO 1999-XO30336	19991217	
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035454	A1	20000622	WO 1999-XP30336	19991217	
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1140087	A1	20011010	EP 1999-965322	19991217	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6331541	B1	20011218	US 1999-465288	19991217	
US 6492400	B1	20021210	US 1999-465287	19991217	
ZA 2001003756	A	20020509	ZA 2001-3756	20010509	
US 20030013741	A1	20030116	US 2001-7172	20011023	
US 6521592	B2	20030218			
US 20040002515	A1	20040101	US 2002-279416	20021024	
US 6875776	B2	20050405			
US 20040006107	A1	20040108	US 2002-279231	20021024	
US 6780857	B2	20040824			
US 20050192291	A1	20050901	US 2004-21042	20041223	
PRIORITY APPLN. INFO.:			US 1998-112717P	P 19981218	
			US 1999-161184P	P 19991022	
			US 1999-161137P	P 19991022	
			US 1999-161222P	P 19991022	
			US 1999-465287	A3 19991217	
			US 1999-465288	A3 19991217	
			US 1999-465948	A3 19991217	
			WO 1999-US30336	W 19991217	
			US 2002-279416	A1 20021024	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 133:43445
GI




AB The title compds. [I; M = absent, CH₂, CH(CH₂Ph), etc.; Q = CH₂, CHR₅, etc.; J, K, L = CH₂, CH(CH₂Ph), etc.; Z = O, S; E = (CH₂)₂, (CH₂)₃, CH₂CH(OH)CH(Ph), etc.; R₁, R₂ = H, alkyl, alkenyl, etc.; R₂ and R₃ may join to form (un)substituted 5-7 membered ring; R₃ = (un)substituted Ph, naphthyl, adamantyl, etc.; R₄ = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/da (oral dosage). [This abstract record is one of 17 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)


RN 275810-67-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)





OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS
RECORD (16 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 124 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:420963 CAPLUS
DOCUMENT NUMBER: 133:43444
TITLE: Preparation of N-ureidoalkyl-piperidines as modulators
of chemokine receptor activity
INVENTOR(S): Ko, Soo; Clark, Cheryl Mcardle; Delucca, George V.;
Duncia, John V.; Santella, Joseph B., III; Wacker,
Dean A.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Co., USA
SOURCE: PCT Int. Appl., 316 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 108
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035453	A1	20000622	WO 1999-US30335	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2347909	A1	20000622	CA 1999-2347909	19991217
WO 2000035453	A1	20000622	WO 1999-XA30335	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035453	A1	20000622	WO 1999-XB30335	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035453	A1	20000622	WO 1999-XC30335	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035453	A1	20000622	WO 1999-XD30335	19991217

W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035453	A1	20000622	WO 1999-XE30335	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035453	A1	20000622	WO 1999-XF30335	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035453	A1	20000622	WO 1999-XG30335	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035453	A1	20000622	WO 1999-XH30335	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
EP 1158980	A1	20011205	EP 1999-965321	19991217
EP 1158980	B1	20050824		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6331541	B1	20011218	US 1999-465288	19991217
US 6486180	B1	20021126	US 1999-465948	19991217
AT 302606	T	20050915	AT 1999-965321	19991217
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
US 20030013741	A1	20030116	US 2001-7172	20011023
US 6521592	B2	20030218		
US 20040002515	A1	20040101	US 2002-279416	20021024
US 6875776	B2	20050405		
US 20040006107	A1	20040108	US 2002-279231	20021024
US 6780857	B2	20040824		
US 20050192291	A1	20050901	US 2004-21042	20041223
PRIORITY APPLN. INFO.:			US 1998-112717P	P 19981218
			US 1999-161137P	P 19991022
			US 1999-161184P	P 19991022
			US 1999-161222P	P 19991022
			US 1999-465287	A3 19991217
			US 1999-465288	A3 19991217
			US 1999-465948	A3 19991217
			WO 1999-US30335	W 19991217
			US 2002-279416	A1 20021024
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 133:43444				
GI				




AB The title compds. [I; M = absent, CH₂, CH(CH₂Ph), etc.; Q = CH₂, CH(CH₂Ph), etc.; J, K, L = CH₂, CH(CH₂Ph), etc.; Z = O, S; E = (CH₂)₂, (CH₂)₃, CH₂CH(OH)CH(Ph), etc.; R₁, R₂ = H, alkyl, alkenyl, etc.; R₂ and R₃ may join to form (un)substituted 5-7 membered ring; R₃ = (un)substituted Ph, naphthyl, adamantyl, etc.; R₄ = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage). [This abstract record is one of 9 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)


RN 275810-67-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 125 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:420962 CAPLUS

DOCUMENT NUMBER: 133:43443

TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Santella, Joseph B. Iii; Wacker, Dean A. K.

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 388 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 108

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035452	A1	20000622	WO 1999-US30334	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2347770	A1	20000622	CA 1999-2347770	19991217
WO 2000035452	A1	20000622	WO 1999-XA30334	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035452	A1	20000622	WO 1999-XB30334	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035452	A1	20000622	WO 1999-XC30334	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035452	A1	20000622	WO 1999-XD30334	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX,				

	NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ,			
	MD, RU, TJ, TM			
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,			
	PT, SE			
WO 2000035452	A1	20000622	WO 1999-XE30334	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX,			
	NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ,			
	MD, RU, TJ, TM			
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,			
	PT, SE			
WO 2000035452	A1	20000622	WO 1999-XF30334	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX,			
	NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ,			
	MD, RU, TJ, TM			
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,			
	PT, SE			
WO 2000035452	A1	20000622	WO 1999-XG30334	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX,			
	NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ,			
	MD, RU, TJ, TM			
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,			
	PT, SE			
WO 2000035452	A1	20000622	WO 1999-XH30334	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX,			
	NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ,			
	MD, RU, TJ, TM			
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,			
	PT, SE			
EP 1161240	A1	20011212	EP 1999-963107	19991217
EP 1161240	B1	20050817		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
	IE, SI, LT, LV, FI, RO			
US 6331541	B1	20011218	US 1999-465288	19991217
TR 2001001859	T2	20011221	TR 2001-1859	19991217
BR 9917038	A	20020402	BR 1999-17038	19991217
JP 2002532427	T	20021002	JP 2000-587772	19991217
NZ 511394	A	20030725	NZ 1999-511394	19991217
AU 770042	B2	20040212	AU 2000-19406	19991217
CN 1206219	C	20050615	CN 1999-814539	19991217
AT 302005	T	20050915	AT 1999-963107	19991217
IN 2001MN00521	A	20050304	IN 2001-MN521	20010501
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
NO 2001002977	A	20010820	NO 2001-2977	20010615
MX 2001006148	A	20010911	MX 2001-6148	20010615
US 20030013741	A1	20030116	US 2001-7172	20011023
US 6521592	B2	20030218		
US 20040002515	A1	20040101	US 2002-279416	20021024
US 6875776	B2	20050405		
US 20040006107	A1	20040108	US 2002-279231	20021024
US 6780857	B2	20040824		
US 20050096325	A1	20050505	US 2004-983367	20041108
US 20050192291	A1	20050901	US 2004-21042	20041223
PRIORITY APPLN. INFO.:			US 1998-112717P	P 19981218
			US 1999-161221P	P 19991022
			US 1999-161137P	P 19991022
			US 1999-161184P	P 19991022
			US 1999-161222P	P 19991022
			US 1999-465287	A3 19991217
			US 1999-465288	A3 19991217
			US 1999-465948	A3 19991217
			US 1999-466442	A3 19991217
			WO 1999-US30334	W 19991217

US 2002-180869

A1 20020626



US 2002-279416

A1 20021024

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 133:43443

GI




AB The title compds. [I; M = absent, CH₂, CH(CH₂Ph), etc.; Q = CH₂, CH(CH₂Ph), etc.; J, K, L = CH₂, CH(CH₂Ph), etc.; Z = O, S; E = (CH₂)₂, (CH₂)₃, CH₂CH(OH)CH(Ph), etc.; R₁, R₂ = H, alkyl, alkenyl, etc.; R₂ and R₃ may join to form (un)substituted 5-7 membered ring; R₃ = (un)substituted Ph, naphthyl, adamantyl, etc.; R₄ = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage). [This abstract record is one of 9 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)


RN 275810-67-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 126 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:420961 CAPLUS

DOCUMENT NUMBER: 133:43442

TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.; Watson, Paul S.; Varnes, Jeffrey G.

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 394 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 108

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035451	A1	20000622	WO 1999-US30332	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				



	RW:	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		PT,	SE														
CA	2350730				A1			20000622		CA	1999-2350730					19991217	
WO	2000035451				A1			20000622		WO	1999-XA30332					19991217	
	W:	AL,	AU,	BR,	CA,	CN,	CZ,	EE,	HU,	IL,	IN,	JP,	KR,	LT,	LV,	MK,	MX,
		NO,	NZ,	PL,	RO,	SG,	SI,	SK,	TR,	UA,	VN,	ZA,	AM,	AZ,	BY,	KG,	KZ,
		MD,	RU,	TJ,	TM												
	RW:	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		PT,	SE														
WO	2000035451				A1			20000622		WO	1999-XB30332					19991217	
	W:	AL,	AU,	BR,	CA,	CN,	CZ,	EE,	HU,	IL,	IN,	JP,	KR,	LT,	LV,	MK,	MX,
		NO,	NZ,	PL,	RO,	SG,	SI,	SK,	TR,	UA,	VN,	ZA,	AM,	AZ,	BY,	KG,	KZ,
		MD,	RU,	TJ,	TM												
	RW:	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		PT,	SE														
WO	2000035451				A1			20000622		WO	1999-XC30332					19991217	
	W:	AL,	AU,	BR,	CA,	CN,	CZ,	EE,	HU,	IL,	IN,	JP,	KR,	LT,	LV,	MK,	MX,
		NO,	NZ,	PL,	RO,	SG,	SI,	SK,	TR,	UA,	VN,	ZA,	AM,	AZ,	BY,	KG,	KZ,
		MD,	RU,	TJ,	TM												
	RW:	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		PT,	SE														
WO	2000035451				A1			20000622		WO	1999-XD30332					19991217	
	W:	AL,	AU,	BR,	CA,	CN,	CZ,	EE,	HU,	IL,	IN,	JP,	KR,	LT,	LV,	MK,	MX,
		NO,	NZ,	PL,	RO,	SG,	SI,	SK,	TR,	UA,	VN,	ZA,	AM,	AZ,	BY,	KG,	KZ,
		MD,	RU,	TJ,	TM												
	RW:	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		PT,	SE														
WO	2000035451				A1			20000622		WO	1999-XE30332					19991217	
	W:	AL,	AU,	BR,	CA,	CN,	CZ,	EE,	HU,	IL,	IN,	JP,	KR,	LT,	LV,	MK,	MX,
		NO,	NZ,	PL,	RO,	SG,	SI,	SK,	TR,	UA,	VN,	ZA,	AM,	AZ,	BY,	KG,	KZ,
		MD,	RU,	TJ,	TM												
	RW:	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		PT,	SE														
WO	2000035451				A1			20000622		WO	1999-XF30332					19991217	
	W:	AL,	AU,	BR,	CA,	CN,	CZ,	EE,	HU,	IL,	IN,	JP,	KR,	LT,	LV,	MK,	MX,
		NO,	NZ,	PL,	RO,	SG,	SI,	SK,	TR,	UA,	VN,	ZA,	AM,	AZ,	BY,	KG,	KZ,
		MD,	RU,	TJ,	TM												
	RW:	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		PT,	SE														
WO	2000035451				A1			20000622		WO	1999-XG30332						

	PT, SE			
WO 2000035451	A1	20000622	WO 1999-XK30332	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035451	A1	20000622	WO 1999-XL30332	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035451	A1	20000622	WO 1999-XM30332	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035451	A1	20000622	WO 1999-XN30332	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035451	A1	20000622	WO 1999-XO30332	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035451	A1	20000622	WO 1999-XP30332	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
EP 1140086	A1	20011010	EP 1999-964297	19991217
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6331541	B1	20011218	US 1999-465288	19991217
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
US 20030013741	A1	20030116	US 2001-7172	20011023
US 6521592	B2	20030218		
US 20040002515	A1	20040101	US 2002-279416	20021024
US 6875776	B2	20050405		
US 20040006107	A1	20040108	US 2002-279231	20021024
US 6780857	B2	20040824		
US 20050192291	A1	20050901	US 2004-21042	20041223
PRIORITY APPLN. INFO.:			US 1998-112717P	P 19981218
			US 1999-161243P	P 19991022
			US 1999-161137P	P 19991022
			US 1999-161184P	P 19991022
			US 1999-161222P	P 19991022
			US 1999-465287	A3 19991217
			US 1999-465288	A3 19991217
			US 1999-465948	A3 19991217
			WO 1999-US30332	W 19991217
			US 2002-279416	A1 20021024


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 133:43442


GI



- AB The title compds. [I; M = absent, CH₂, CH(CH₂Ph), etc.; Q = CH₂, CH(CH₂Ph), etc.; J, K, L = CH₂, CH(CH₂Ph), etc.; Z = O, S; E = (CH₂)₂, (CH₂)₃, CH₂CH(OH)CH(Ph), etc.; R₁, R₂ = H, alkyl, alkenyl, etc.; R₂ and R₃ may join to form (un)substituted 5-7 membered ring; R₃ = (un)substituted Ph, naphthyl, adamantyl, etc.; R₄ = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage). [This abstract record is one of 17 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]
- IT 275810-67-8P 275810-68-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)
- RN 275810-67-8 CAPLUS
- CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



- RN 275810-68-9 CAPLUS
- CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)





OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS
RECORD (13 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 127 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:420959 CAPLUS
DOCUMENT NUMBER: 133:43441
TITLE: Preparation of N-ureidoalkyl-piperidines as modulators
of chemokine receptor activity
INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.;
Santella, Joseph B., III; Gardner, Daniel S.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 327 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 108
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035449	A1	20000622	WO 1999-US30292	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2346933	A1	20000622	CA 1999-2346933	19991217
WO 2000035449	A1	20000622	WO 1999-XA30292	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035449	A1	20000622	WO 1999-XB30292	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035449	A1	20000622	WO 1999-XC30292	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035449	A1	20000622	WO 1999-XD30292	19991217

W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035449	A1	20000622	WO 1999-XE30292	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035449	A1	20000622	WO 1999-XF30292	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035449	A1	20000622	WO 1999-XG30292	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
WO 2000035449	A1	20000622	WO 1999-XH30292	19991217
W:	AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
EP 1156807	A1	20011128	EP 1999-968144	19991217
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6331541	B1	20011218	US 1999-465288	19991217
TR 2001001859	T2	20011221	TR 2001-1859	19991217
CN 1206219	C	20050615	CN 1999-814539	19991217
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
US 20030013741	A1	20030116	US 2001-7172	20011023
US 6521592	B2	20030218		
US 20040002515	A1	20040101	US 2002-279416	20021024
US 6875776	B2	20050405		
US 20040006107	A1	20040108	US 2002-279231	20021024
US 6780857	B2	20040824		
US 20050096325	A1	20050505	US 2004-983367	20041108
US 20050192291	A1	20050901	US 2004-21042	20041223
PRIORITY APPLN. INFO.:			US 1998-112717P	P 19981218
			US 1999-161221P	P 19991022
			US 1999-161137P	P 19991022
			US 1999-161184P	P 19991022
			US 1999-161222P	P 19991022
			US 1999-465287	A3 19991217
			US 1999-465288	A3 19991217
			US 1999-465948	A3 19991217
			US 1999-466442	A3 19991217
			WO 1999-US30292	W 19991217
			US 2002-180869	A1 20020626
			US 2002-279416	A1 20021024
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 133:43441				
GI				




AB The title compds. [I; M = absent, CH₂, CH(CH₂Ph), etc.; Q = CH₂, CHR₅, etc.; J, K, L = CH₂, CH(CH₂Ph), etc.; Z = O, S; E = (CH₂)₂, (CH₂)₃, CH₂CH(OH)CH(Ph), etc.; R₁, R₂ = H, alkyl, alkenyl, etc.; R₂ and R₃ may join to form (un)substituted 5-7 membered ring; R₃ = (un)substituted Ph, naphthyl, adamantyl, etc.; R₄ = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage). [This abstract record is one of 9 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)


RN 275810-67-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 128 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:401486 CAPLUS

DOCUMENT NUMBER: 133:43247

TITLE: Preparation of
N β -cyclohexylcarbonyl- β -amino- α -
ketoalkanamides as cathepsin K inhibitors

INVENTOR(S): Hosoda, Akihiko; Kobayashi, Nobuo; Tanabe, Naoko;
Koji, Tsuneo; Shibata, Masahiro; Sekine, Akihiro;
Dozen, Masaharu

PATENT ASSIGNEE(S): Fujirebio Kabushiki Kaisha, Japan; Seikagaku
Corporation

SOURCE: Eur. Pat. Appl., 104 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1008592	A2	20000614	EP 1999-402811	19991112
EP 1008592	A3	20000802		
EP 1008592	B1	20060201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2000204071	A	20000725	JP 1999-313319	19991104
JP 3892187	B2	20070314		
US 6117870	A	20000912	US 1999-437438	19991110
KR 2000035402	A	20000626	KR 1999-49831	19991111
EP 1616867	A1	20060118	EP 2005-18360	19991112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
EP 1616859	A1	20060118	EP 2005-18361	19991112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
EP 1619189	A1	20060125	EP 2005-18359	19991112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 316967	T	20060215	AT 1999-402811	19991112
ES 2258318	T3	20060816	ES 1999-402811	19991112
JP 2004277427	A	20041007	JP 2004-144158	20040513
JP 2004277428	A	20041007	JP 2004-144160	20040513
JP 4265993	B2	20090520		
JP 2004277429	A	20041007	JP 2004-144162	20040513

JP 4312657	B2	20090812		
JP 2004292456	A	20041021	JP 2004-144161	20040513
JP 4312656	B2	20090812		
JP 2004300159	A	20041028	JP 2004-204765	20040712
JP 4312672	B2	20090812		


PRIORITY APPLN. INFO.:

JP 1998-322283	A	19981112
JP 1999-313319	A3	19991104
EP 1999-402811	A3	19991112

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 133:43247

GI



AB R1CR2CONHCHR2COCOR3 [I; R2 = (heteroatom-interrupted) alkylene; R1 = (un)substituted NH2, -alk(en)yl, -alkoxy, -H2NCO, etc.; R2 = H, alkyl, (un)substituted aryl, etc.; R3 = H, OR4, NR5R6; R4-R6 = H, (cyclo)alkyl, aryl, etc.] were prepared Thus, 1-[(morpholinocarbonyl)amino]cyclohexanecarboxylic acid was amidated by (3S)-H2NCHBuCH(OH)CONHR5 (R5 = cyclopentyl) (preparation each given) and the product oxidized to give title compound II. Data for biol. activity of I were given.


IT 274685-10-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N β -cyclohexylcarbonyl- β -amino- α -ketoalkanamides as cathepsin K inhibitors)

RN 274685-10-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[[[(1S)-1-[2-(cyclopentylamino)-2-oxoacetyl]pentyl]amino]carbonyl]cyclohexyl]-4-methoxy- (CA INDEX NAME)

Absolute stereochemistry.




IT 274686-18-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N β -cyclohexylcarbonyl- β -amino- α -
ketoalkanamides as cathepsin K inhibitors)

RN 274686-18-9 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[[[(4-methoxy-1-piperidiny)carbonyl]amino]-
(CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS
RECORD (18 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 129 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:314688 CAPLUS

DOCUMENT NUMBER: 132:334455

TITLE: 2-Ureidothiazole derivatives, process for their
preparation, and their use as antitumor agents

INVENTOR(S): Pevarello, Paolo; Amici, Raffaella; Traquandi,
Gabriella; Villa, Manuela; Vulpetti, Anna; Isacchi,
Antonella

PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000026203	A1	20000511	WO 1999-EP8307	19991027
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2347060	A1	20000511	CA 1999-2347060	19991027
BR 9914868	A	20010703	BR 1999-14868	19991027
EP 1124811	A1	20010822	EP 1999-953959	19991027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2001004167	A2	20020328	HU 2001-4167	19991027
HU 2001004167	A3	20031229		
JP 2002528538	T	20020903	JP 2000-579592	19991027
NZ 510967	A	20031031	NZ 1999-510967	19991027
AU 771166	B2	20040318	AU 2000-10447	19991027
ZA 2001002869	A	20011010	ZA 2001-2869	20010406
NO 2001002058	A	20010628	NO 2001-2058	20010426
MX 2001004277	A	20020208	MX 2001-4277	20010427
US 20030187040	A1	20031002	US 2001-830668	20010430
US 6863647	B2	20050308		
IN 2001CN00755	A	20050304	IN 2001-CN755	20010529
US 20040157827	A1	20040812	US 2004-770019	20040202

AU 2004202678
PRIORITY APPLN. INFO.:

A1 20040715

AU 2004-202678

20040618

GB 1998-23873

A 19981030

AU 2000-10447

A3 19991027

WO 1999-EP8307

W 19991027


US 2001-830668

A1 20010430

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 132:334455

GI



AB The title 2-ureido-1,3-thiazole derivs. I and their pharmaceutically acceptable salts are disclosed [wherein R = halo, nitro, (un)substituted amino, C1-6 alkyl, C3-6 cycloalkyl, aryl, or arylalkyl; R1 = (un)substituted C1-6 alkyl, 3- to 6-membered carbocycle or 5- to 7-membered heterocycle, aryl, arylcarbonyl, or arylalkyl; R2 = H, straight or branched C1-4 alkyl, C2-4 alkenyl, or alkynyl; or NR1R2 = (un)substituted, optionally benzo-condensed or bridged 5- to 7-membered heterocycle, or 9- to 11-membered spiro-heterocycle]. The compds. are active as cdk/cyclin inhibitors, and are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity. The proliferative disorders include cancer and a wide variety of other conditions, such as Alzheimer's disease, viral infections, autoimmune diseases, and neurodegenerative disorders. Over 230 invention compds. are claimed and/or prepared in examples. For instance, reaction of Ph isocyanate with 2-amino-5-bromo-1,3-thiazole hydrobromide in the presence of Et3N gave title compound I [R = Br, R1 = Ph, R2 = H]. The similarly prepared title compound I [R = iso-Pr, R1 = 3,5-dimethylphenyl, R2 = H] inhibited cdk2/cyclin A complex in vitro with an IC50 of 0.56 μ M.


IT 267430-42-2P, 4-Hydroxy-N-(5-isopropyl-1,3-thiazol-2-yl)-1-piperidinecarboxamide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of ureidothiazole derivs. as antitumor agents)

RN 267430-42-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[5-(1-methylethyl)-2-thiazolyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (42 CITINGS)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 130 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 2000:260231 CAPLUS

DOCUMENT NUMBER: 132:293770
 TITLE: Preparation of 6-substituted
 pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent
 kinase inhibitors
 INVENTOR(S): Markwalder, Jay A.; Seitz, Steven P.; Sherk, Susan R.
 PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
 SOURCE: PCT Int. Appl., 155 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021926	A2	20000420	WO 1999-US23512	19991013
WO 2000021926	A3	20000803		
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6531477	B1	20030311	US 1999-416584	19991012
CA 2345809	A1	20000420	CA 1999-2345809	19991013
CA 2345809	C	20100413		
EP 1121363	A2	20010808	EP 1999-951875	19991013
EP 1121363	B1	20041222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537223	T	20021105	JP 2000-575835	19991013
AT 285411	T	20050115	AT 1999-951875	19991013
PT 1121363	E	20050429	PT 1999-951875	19991013
ES 2235528	T3	20050701	ES 1999-951875	19991013
US 20020013328	A1	20020131	US 2001-794825	20010227
US 6559152	B2	20030506		
CA 2431038	A1	20020906	CA 2002-2431038	20020227
WO 2002067654	A2	20020906	WO 2002-US6002	20020227
WO 2002067654	A3	20021031		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002255614	A1	20020912	AU 2002-255614	20020227
EP 1383769	A2	20040128	EP 2002-725023	20020227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520407	T	20040708	JP 2002-567036	20020227
PRIORITY APPLN. INFO.:				
			US 1998-103957P	P 19981013
			US 1999-416584	A1 19991012
			WO 1999-US23512	W 19991013
			US 2001-794825	A 20010227
			WO 2002-US6002	W 20020227

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 132:293770
 GI



I



II


AB The title compds. [I, alternatively represented by tautomer II; Q = H, OH, Me, Et; Y = F, Cl, Br, I; Z = N, CR₆; R₁ = (un)substituted Ph, naphthyl, tropone, etc.; R₂ = alkyl, alkenyl, alkynyl, etc.; R₃ = H, F, Cl, etc.; R₄ = H, F, Cl, etc.; R₅ = H, alkyl, F, etc.; R₆ = H, F, Cl, etc.] which are potent inhibitors of the class of enzymes known as cyclin dependent kinases (no data), which relate to the catalytic subunits cyclin dependent kinase 1-8 and their regulatory subunits known as cyclins A-H, K, N, and T, and are useful in treating cancer or other proliferative diseases, were prepared Thus, reacting 5-amino-3-methylthio-1-(2,4,6-trichlorophenyl)pyrazole-4-carboxamide with 3-methoxyphenylacetyl chloride in the presence of NaOEt in EtOH afforded 92% I [Q = H; Y = Cl; R₁ = 3-MeOC₆H₄; R₂ = MeS; R₃, R₄ = H; R₅ = Cl; Z = CCl].

IT 264137-92-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors)

RN 264137-92-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[3-[[4,5-dihydro-3-(1-methylethyl)-4-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]methyl]phenyl]-4-hydroxy- (CA INDEX NAME)




OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 131 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:42145 CAPLUS


DOCUMENT NUMBER: 132:208061
 TITLE: Polyhydroxylated N-(thio)carbamoyl piperidines: nojirimycin-type glycomimetics with controlled anomeric configuration
 AUTHOR(S): Garcia-Moreno, M. Isabel; Mellet, Carmen Ortiz; Fernandez, Jose M. Garcia
 CORPORATE SOURCE: Departamento de Quimica Organica, Facultad de Quimica, Universidad de Sevilla, Seville, E-41071, Spain
 SOURCE: Tetrahedron: Asymmetry (1999), 10(22), 4271-4275
 CODEN: TASYE3; ISSN: 0957-4166
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB N-(Thio)carbamoyl D-xylo-nojirimycin derivs. have been prepared by intramol. rearrangement of sugar thiourea precursors under basic conditions. The stereochem. at the aminoketal stereocenter is under stereoelectronic control, with the diastereomer having the pseudoanomeric group in axial orientation being obtained in all cases.
 IT 260544-78-3P 260544-79-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of polyhydroxylated N-(thio)carbamoyl piperidines, nojirimycin-type glycomimetics with controlled anomeric configuration)
 RN 260544-78-3 CAPLUS
 CN 1-Piperidinecarboxamide, 2,3,4,5-tetrahydroxy-N-phenyl-, (2R,3R,4S,5R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 260544-79-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-β-D-glucopyranosyl-2,3,4,5-tetrahydroxy-, (2R,3R,4S,5R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 132 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:811221 CAPLUS
DOCUMENT NUMBER: 132:35695
TITLE: Preparation of carbon substituted aminothiazole inhibitors of cyclin dependent kinases
INVENTOR(S): Rawlins, David B.; Kimball, S. David; Misra, Raj N.; Kim, Kyoung S.; Webster, Kevin R.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965884	A1	19991223	WO 1999-US13034	19990611
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6407124	B1	20020618	US 1999-329616	19990610
CA 2332325	A1	19991223	CA 1999-2332325	19990611
AU 9944311	A	20000105	AU 1999-44311	19990611
AU 768751	B2	20040108		
EP 1087951	A1	20010404	EP 1999-927401	19990611
EP 1087951	B1	20050209		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002518380	T	20020625	JP 2000-554710	19990611
AT 288904	T	20050215	AT 1999-927401	19990611
ES 2237919	T3	20050801	ES 1999-927401	19990611
US 20020165259	A1	20021107	US 2002-112133	20020329
US 6720347	B2	20040413		
PRIORITY APPLN. INFO.:			US 1998-89747P	P 19980618
			US 1999-329616	A3 19990610
			WO 1999-US13034	W 19990611


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 132:35695

GI



I



II

AB The title compds. [I; R1 = R2, COR3, CONH2, etc.; R2 = alkyl, cycloalkyl, heterocycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; A = (CR7R8)m(CR5R6)nR4 (wherein n = 0-2; m = 1-2 but both n and m cannot be 2), (CR7R8)jY(CR5R6)iR4 (i, j = 0-1 but cannot both be 1; Y =

(un)substituted alkene, alkyne, any 2 adjacent carbon atoms of a cycloalkyl or cycloheteroalkyl ring of 3-7 atoms); R4 = alkyl, cycloalkyl, heterocycloalkyl, etc.; R5-R8 = H, alkyl, cycloalkyl, etc.], protein kinase inhibitors (no data) which are useful in the treatment of proliferative diseases, for example, cancer, inflammation, and arthritis, and also in the treatment of Alzheimer's disease, and cardiovascular disease, were prepared E.g., a multi-step synthesis of (E)-II, starting with 2-aminothiazol-5-ylcarboxaldehyde, was given.

IT 252661-22-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carbon substituted aminothiazole inhibitors of cyclin dependent kinases)

RN 252661-22-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-4-hydroxy- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 27 THERE ARE 27 CAPLUS RECORDS THAT CITE THIS RECORD (43 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 133 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:784087 CAPLUS
DOCUMENT NUMBER: 132:22961
TITLE: Preparation of isothiazolamide urea derivatives as anticancer agents
INVENTOR(S): Larson, Eric Robert; Noe, Mark Carl; Gant, Thomas George
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962890	A1	19991209	WO 1999-IB797	19990503
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2333703	A1	19991209	CA 1999-2333703	19990503
CA 2333703	C	20050614		

CA 2475113	A1	19991209	CA 1999-2475113	19990503
CA 2475113	C	20080318		
AU 9933421	A	19991220	AU 1999-33421	19990503
BR 9910900	A	20010213	BR 1999-10900	19990503
EP 1084114	A1	20010321	EP 1999-914724	19990503
EP 1084114	B1	20040908		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO

TR 2000003478	T2	20010321	TR 2000-3478	19990503
HU 2001002422	A2	20020529	HU 2001-2422	19990503
HU 2001002422	A3	20020628		
JP 2002517384	T	20020618	JP 2000-552102	19990503
JP 3735254	B2	20060118		
NZ 507009	A	20031128	NZ 1999-507009	19990503
AT 275553	T	20040915	AT 1999-914724	19990503
CN 1172918	C	20041027	CN 1999-806837	19990503
PT 1084114	E	20041231	PT 1999-914724	19990503
ES 2226368	T3	20050316	ES 1999-914724	19990503
CN 1616386	A	20050518	CN 2004-10076926	19990503
IL 138776	A	20060705	IL 1999-138776	19990503
CZ 298559	B6	20071107	CZ 2000-4451	19990503
PL 198151	B1	20080530	PL 1999-344691	19990503
SK 286405	B6	20080905	SK 2000-1778	19990503
US 6235764	B1	20010522	US 1999-316837	19990521
TW 561154	B	20031111	TW 1999-88108991	19990531
ZA 9903752	A	20001204	ZA 1999-3752	19990603
AP 1309	A	20040914	AP 1999-1560	19990603
BG 104998	A	20010731	BG 2000-104998	20001128
BG 65104	B1	20070228		
NO 2000006071	A	20001130	NO 2000-6071	20001130
NO 318798	B1	20050509		
MX 2000011849	A	20010521	MX 2000-11849	20001130
HR 2000000835	A2	20011231	HR 2000-835	20001204
HR 2000000835	B1	20080131		
US 20010020034	A1	20010906	US 2001-803296	20010309
US 6548526	B2	20030415		
HK 1036982	A1	20050401	HK 2001-107830	20011108
US 20030149048	A1	20030807	US 2003-357093	20030203
US 7405218	B2	20080729		
AU 2004202433	A1	20040701	AU 2004-202433	20040602
AU 2004202433	B2	20070419		
JP 2005002122	A	20050106	JP 2004-209396	20040716
AU 2007203344	A1	20070809	AU 2007-203344	20070718
US 20080300249	A1	20081204	US 2008-181803	20080729



PRIORITY APPLN. INFO.:

US 1998-87963P	P	19980604
AU 1999-33421	A3	19990503
CA 1999-2333703	A3	19990503
JP 2000-552102	A3	19990503
WO 1999-IB797	W	19990503
US 1999-316837	A3	19990521
US 2001-803296	A3	20010309
US 2003-357093	A1	20030203
AU 2004-202433	A3	20040602

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 132:22961

GI



AB Title compds. (I) [X1 = O or S; R1 = H, (un)substituted alkyl, alkenyl, alkynyl, acyl, (CH2)t(hetero)aryl, C(O)(CH2)t(hetero)aryl, etc.; t = 0-5; R2 = R1, SO2(CH2)t(hetero)aryl, etc.; or R1 and R2 taken together with the attached N = 4-10 membered (un)substituted poly- or monocyclic ring or 5-10 membered (un)substituted heteroaryl ring; R3 = H, (un)substituted alkyl, alkenyl, alkynyl, (CH2)t(hetero)aryl, etc.] were prepared for use in the treatment of hyperproliferative disorders, such as cancer. Thus, 3-(4-cyano-3-mercaptoisothiazol-5-yl)-1,1-dimethylurea (preparation given) was alkylated with 1-iodohexane (51%) and the product treated with concentrated H2SO4 to yield the isothiazolamide (II) (78%). I are inhibitors of receptor tyrosine kinases and bind to or modulate the KDR/FLK-1 receptor (no data) and may be used to treat disorders related to vasculogenesis or angiogenesis.


IT 1101899-44-8

RL: PRPH (Prophetic)

(Preparation of isothiazolamide urea derivatives as anticancer agents)

RN 1101899-44-8 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



OS.CITING REF COUNT:	25	THERE ARE 25 CAPLUS RECORDS THAT CITE THIS RECORD (28 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:733849 CAPLUS
DOCUMENT NUMBER: 131:337032
TITLE: Preparation of N-(1-phenylcycloalkyl)piperidines and
analogs as neuropeptide Y1 receptor ligands
INVENTOR(S): Blum, Charles A.; Hutchison, Alan; Peterson, John M.
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 5985873	A	19991116	US 1997-897044	19970718
PRIORITY APPLN. INFO.:			US 1997-897044	19970718
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE				
OTHER SOURCE(S):	MARPAT 131:337032			
GI				





AB Title compds. [I; R = Ph, pyridyl, thienyl, pyrimidinyl, etc.; R1,R2 = H or alkyl; R3,R4 = H, alkyl, alkoxy; 1 of X1-X3 = NR7COR8 and the others = H; R7 = H or alkyl; R8 = (thio)morpholino, (4-substituted) piperidino, (4-alkyl) piperazino; Z = O, NR5, CR5R6; R5 = alkyl, phenyl(alkyl), pyridyl(alkyl); R6 = H, NH2, alkyl, alkoxy, etc.; Z1 = (CH2)1-3] were prepared as neuropeptide Y1 receptor ligands (no data). Thus, 4-methylcyclohexanone was condensed with 1-phenylpiperazine and KCN and the product condensed with 3-[(Me3Si)2N]C6H4MgCl to give, after deprotection, cis-I (R = Ph, R1-R4 = X1 = X3 = H, Z = CHMe, Z1 = CH2CH2)(II; X2 = NH2) which was condensed with COCl2 and 1,4-dioxa-8-azaspiro[4.5]decane to give, after hydrolysis, II (X2 = 4-oxopiperidinocarbonylamino).

IT 249732-72-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(1-phenylcycloalkyl)piperidines and analogs as neuropeptide Y1 receptor ligands)

RN 249732-72-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[3-[cis-4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]-, hydrochloride (1:?) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 135 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1999:325920 CAPLUS
 DOCUMENT NUMBER: 130:352265
 TITLE: Preparation of aminothiazole inhibitors of cyclin dependent kinases
 INVENTOR(S): Kim, Kyoung S.; Kimball, S. David; Poss, Michael A.; Misra, Raj N.; Cai, Zhen-Wei; Rawlins, David B.; Webster, Kevin; Hunt, John T.; Han, Wen-Ching
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 132 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924416	A1	19990520	WO 1998-US23197	19981102
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2309551	A1	19990520	CA 1998-2309551	19981102
CA 2309551	C	20060328		
AU 9912955	A	19990531	AU 1999-12955	19981102
AU 730607	B2	20010308		
TR 2000001344	T2	20000921	TR 2000-1344	19981102
BR 9814124	A	20001003	BR 1998-14124	19981102
EP 1042307	A1	20001011	EP 1998-956431	19981102
EP 1042307	B1	20071003		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

CN 1278806	A	20010103	CN 1998-811091	19981102
CN 1160343	C	20040804		
JP 2001522842	T	20011120	JP 2000-520430	19981102
JP 4344084	B2	20091014		
HU 2000004559	A2	20020429	HU 2000-4559	19981102
NZ 503828	A	20030328	NZ 1998-503828	19981102
RU 2211839	C2	20030910	RU 2000-115305	19981102
IL 135589	A	20040620	IL 1998-135589	19981102
CZ 297907	B6	20070425	CZ 2000-1744	19981102
AT 374771	T	20071015	AT 1998-956431	19981102
PT 1042307	E	20071115	PT 1998-956431	19981102
ES 2296347	T3	20080416	ES 1998-956431	19981102
TW 593292	B	20040621	TW 1998-87118625	19981109
ZA 9810332	A	20000511	ZA 1998-10332	19981111
EG 24028	A	20080326	EG 1998-1406	19981112
NO 2000002153	A	20000511	NO 2000-2153	20000427
NO 316773	B1	20040503		
MX 2000004488	A	20001110	MX 2000-4488	20000509
HK 1029109	A1	20080403	HK 2000-107675	20001130
PRIORITY APPLN. INFO.:			US 1997-65195P	P 19971112
			WO 1998-US23197	W 19981102
OTHER SOURCE(S):		MARPAT 130:352265		
GI				




AB The title compds. I [R1, R2 = H, F, alkyl; R3 = aryl, heteroaryl; R4 = H, alkyl, cycloalkyl, aryl, etc.; R5 = H, alkyl; m = 0-2; n = 1-3] were prepared I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example cancer, inflammation and arthritis (no data). E.g., N-[5-[(5-ethyl-2-oxazolylyl)methyl]thio]-2-thiazolylyl]acetamide was prepared

IT 224437-73-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminothiazole inhibitors of cyclin dependent kinases)

RN 224437-73-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-[(5-ethyl-2-oxazolylyl)methyl]thio]-2-thiazolylyl]-4-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 36 THERE ARE 36 CAPLUS RECORDS THAT CITE THIS
RECORD (51 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 136 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:261205 CAPLUS
DOCUMENT NUMBER: 130:267220
TITLE: Practical synthesis of ureas
INVENTOR(S): Thavonekham, Bounkham
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: Can. Pat. Appl., 39 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2215585	A1	19980317	CA 1997-2215585	19970916
CA 2215585	C	20040420		
US 5925762	A	19990720	US 1997-931006	19970915
PRIORITY APPLN. INFO.:			US 1996-26202P	P 19960917

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 130:267220; MARPAT 130:267220

AB The title process comprises treating Ph carbamates with an approx.
stoichiometric amount of amine in DMSO at ambient temperature Thus,
4-(MeO2C)C6H4NH2 was amidated by ClCO2Ph and the product condensed with
HNBu2 to give 94% (this step) 4-(MeO2C)C6H4NHCONBu2.


IT 199729-06-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
(Preparation)
(practical synthesis of ureas)

RN 199729-06-1 CAPLUS

CN 1,2-Piperidinedicarboxamide, N1-(4-acetylphenyl)-N2-(1,1-dimethylethyl)-4-
hydroxy-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L4 ANSWER 137 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:126872 CAPLUS

DOCUMENT NUMBER: 130:196506

TITLE: Derivatives of 2,5- and 3,5-disubstituted anilines,
their preparation, and use as potassium channel
openers

INVENTOR(S): Dorwald, Florencio Zaragoza; Hansen, John Bondo;
Mogensen, John Patrick; Tagmose, Tina Moller; Pirotte,
Bernard; Lebrun, Philippe; De Tullio, Pascal; Boverie,
Stephane; Delarge, Jacques

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9907672	A1	19990218	WO 1998-DK337	19980724
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9885341	A	19990301	AU 1998-85341	19980724
EP 1019367	A1	20000719	EP 1998-936271	19980724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2003524574	T	20030819	JP 2000-507208	19980724
IN 1998MA01741	A	20050304	IN 1998-MA1741	19980804
ZA 9807026	A	20000207	ZA 1998-7026	19980805
PRIORITY APPLN. INFO.:			DK 1997-906	A 19970805
			US 1997-55193P	P 19970811
			WO 1998-DK337	W 19980724

OTHER SOURCE(S): MARPAT 130:196506

GI




AB Substituted anilines I [R1, R2 = H, CF3, halo, provided that both R1 and R2 \neq H; R3 = CF3 or halo; R4 = (un)substituted alkyl or YR5; Y = O or NR6; R5, R6 = (un)substituted alkyl; or R5 and R6 form a 3- to 8-membered ring; X = O or S], their compns., and methods for preparing them are described. I are useful for the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the urogenital system, the gastrointestinal system and the endocrinol. system. In particular, the compds. are claimed as potassium channel openers useful in the treatment of endocrinol. diseases such as diabetes. Approx. 220 compds. are listed and claimed, and synthetic examples for several are provided. For instance, reaction of 2,4-dichlorobenzyl isocyanate with 3,5-bis(trifluoromethyl)aniline in PhMe at 90° in the presence of Et3N gave title compound II in 34% yield. The most active compds. showed IC50 values of 600 nM in an assay for potassium channel openers.

IT 220636-24-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of disubstituted aniline derivs. as potassium channel openers)

RN 220636-24-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-
 (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 138 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:87720 CAPLUS

DOCUMENT NUMBER: 128:154098

ORIGINAL REFERENCE NO.: 128:30372h,30373a

TITLE: Preparation of certain substituted benzylamine derivatives such as amides of cis-1-(3-aminophenyl)-1-(4-phenyl-1-piperazinyl)-4-methylcyclohexane as a new class of neuropeptide Y1 specific ligands

INVENTOR(S): Blum, Charles A.; Hutchison, Alan; Peterson, John M.


PATENT ASSIGNEE(S): Neurogen Corp., USA

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803493	A1	19980129	WO 1997-US12616	19970718
W: CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2260982	A1	19980129	CA 1997-2260982	19970718
EP 915860	A1	19990519	EP 1997-934218	19970718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000515151	T	20001114	JP 1998-507103	19970718
MX 9900868	A	20000331	MX 1999-868	19990122
PRIORITY APPLN. INFO.:			US 1996-22329P	P 19960723
			WO 1997-US12616	W 19970718
OTHER SOURCE(S):		MARPAT 128:154098		
GI				



AB The title compds. [I; one of X1, X2 and X3 = II and the remaining X1, X2 and X3 = H; W = H, C1-6 alkyl; Y = C, N, O, S; when Y = C then ZZ1 = N(OH), O, O(CH2)mO (wherein m = 2-3) or Z1 = H and Z = H, OH, NH2, etc.; when Y = N then Z = H, C1-6 alkyl and Z1 does not exist; Ar = (un)substituted Ph, pyridyl, thienyl, pyrimidyl; B = S, O, N(R5), C(R5)(R6); n = 1-3; R1, R2 = H, C1-6 alkyl; R3, R4 = H, C1-6 alkyl, C1-6 alkoxy; R5 = H, C1-6 alkyl, Ph, etc.; R6 = H, OH, NH2, etc.], useful in the diagnosis and treatment of feeding disorders such as obesity and bulimia and cardiovascular diseases such as essential hypertension and congestive heart failure due to the binding of these compds. to human neuropeptide Y1 receptors, were prepared Thus, treatment of

cis-1-(3-aminophenyl)-1-(4-phenyl-1-piperazinyl)-4-methylcyclohexane (preparation described) with phosgene in the presence of Et₃N in CH₂Cl₂ followed by addition of 1,4-dioxo-8-azaspiro[4.5]decane afforded the title compound cis-III. Compds. I are effective at 0.1-140 mg/kg/day.

IT 202472-22-8P 202472-28-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of certain substituted benzylamine derivs. such as amides of cis-1-(3-aminophenyl)-1-(4-phenyl-1-piperazinyl)-4-methylcyclohexane as a new class of neuropeptide Y1 specific ligands)

RN 202472-22-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[3-[cis-4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 202472-28-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[3-[cis-4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl


OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD

(5 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 139 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1997:731400 CAPLUS
 DOCUMENT NUMBER: 128:3549
 ORIGINAL REFERENCE NO.: 128:767a,770a
 TITLE: Preparation of N-(2,5-dihydroxyphenyl)urea derivatives having antioxidant and active oxygen-quenching activities
 INVENTOR(S): Suzuki, Toshikazu; Omizu, Hiroshi; Hashimura, Yoshimasa; Kubota, Hitoshi; Saito, Keiko
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09278737	A	19971028	JP 1997-28583	19970213
PRIORITY APPLN. INFO.:			JP 1996-28843	A 19960216
OTHER SOURCE(S):	MARPAT	128:3549		


GI



I



II



III

AB The title phenol derivs. [I; R = H, lower alkyl or alkoxy; R1 = lower alkyl; W = O, S, NR5; wherein R5 = H, lower alkyl, aryl, OH, lower alkoxy; R21 = substituted alkyl; R3 = H, (un)substituted lower alkyl; or NR21R3 = N-containing heterocyclyl] and pharmacol. acceptable salts thereof are prepared by reaction of 2,5-dihydroxyaniline derivs. (II; R, R1 = same as above; R4 = protecting group for the HO group) with COCl2 or triphosgene and then with HNR21R3 (R3, R21 = same as above) followed by deprotection. These compds. I also possess excellent activities for inhibiting lipid peroxidn., foam cell formation of macrophages, oxidative LDL formation, ACAT, and reperfusion-induced arrhythmia and are reduced in toxicity and


thereby are useful for treatment and prevention of arteriosclerosis, ischemic diseases such as cerebral and myocardial infarction, cell damages during ischemia and/or reperfusion, inflammation, and arrhythmia (no data). Thus, a cooled (-78°) solution of COCl₂ in CH₂Cl₂ was added dropwise to a solution of (2-amino-4-methoxyphenoxy)methoxymethane and Et₃N in CH₂Cl₂ and after warming to 0°, the solvent was evaporated under reduced pressure to give a residue. The latter residue was dissolved in CH₂Cl₂, followed by adding dropwise a solution of 2-(4-ethoxycarbonylmethoxyphenyl)ethylamine hydrochloride and Et₃N in CH₂Cl₂, and the resulting mixture was stirred at room temperature for 1 h to give,

after treatment with a mixture of concentrated HCl and EtOH, the title compound (III).

IT 198756-65-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-(dihydroxyphenyl)urea derivs. having antioxidant and active oxygen-quenching activities for treatment of diseases)

RN 198756-65-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(diphenylmethoxy)-N-(2-hydroxy-5-methoxyphenyl)-
 (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)

L4 ANSWER 140 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1997:702201 CAPLUS

DOCUMENT NUMBER: 128:34510

ORIGINAL REFERENCE NO.: 128:6801a,6804a

TITLE: A practical synthesis of ureas from phenyl carbamates

AUTHOR(S): Thavonekham, Bounkham

CORPORATE SOURCE: Bio-Mega Research Division, Boehringer Ingelheim Ltd.,
 Laval, QC, H7S 2G5, Can.

SOURCE: Synthesis (1997), (10), 1189-1194

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Thieme

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 128:34510

AB Using DMSO as solvent, a mild and efficient procedure for the synthesis of unsym. N,N'-disubstituted ureas from Ph carbamates is described. The carbamates are treated with a stoichiometric amount of amine at ambient temperature, generating the ureas in high yield and high purity. The reaction is mild, fast, and easily scaled up.

IT 199729-06-1P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of ureas from Ph carbamates)

RN 199729-06-1 CAPLUS

CN 1,2-Piperidinedicarboxamide, N1-(4-acetylphenyl)-N2-(1,1-dimethylethyl)-4-hydroxy-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




OS.CITING REF COUNT: 34 THERE ARE 34 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)

L4 ANSWER 141 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1996:751800 CAPLUS
 DOCUMENT NUMBER: 126:31225
 ORIGINAL REFERENCE NO.: 126:6353a,6356a
 TITLE: Preparation of 1H-pyrazolo[3,4-d]pyrimidin-4-one derivatives as phosphodiesterase inhibitors
 INVENTOR(S): Oota, Tomoki; Taguchi, Minoru; Kawashima, Yutaka; Hatayama, Katsuo; Tomizawa, Kazuyuki
 PATENT ASSIGNEE(S): Taisho Pharma Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08253484	A	19961001	JP 1996-5930	19960117
JP 3713783	B2	20051109		
PRIORITY APPLN. INFO.:			JP 1995-6986	A 19950120
OTHER SOURCE(S):	MARPAT	126:31225		

GI




AB Title compds. I [R1 = C1-4 alkyl; X = phenoxy, NR2R3; R2, R3 = H, C2-4 hydroxyalkyl, or NR2R3 = morpholino, piperidino, etc.], phosphodiesterase inhibitors and therefore useful for treatment of hypertension and other cardiovascular diseases, (no data), are prepared Thus, I [R1 = Pr, X = PhO] was prepared from 6-(5-amino-2-propoxyphenyl)-4,5-dihydro-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-one (preparation given) and Ph chloroformate. This was further reacted with morpholine to give I [R1 = Pr, X = morpholino]. In an in vitro study, this had an IC50 of 2.4 μ M against phosphodiesterase.

IT 184356-81-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1H-pyrazolo[d]pyrimidinone derivs. as phosphodiesterase inhibitors)

RN 184356-81-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[3-(4,5-dihydro-1,3-dimethyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-ethoxyphenyl]-4-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L4 ANSWER 142 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:446568 CAPLUS

DOCUMENT NUMBER: 125:114672

ORIGINAL REFERENCE NO.: 125:21527a,21530a

TITLE: Preparation of quinazoline derivatives as cyclic GMP phosphodiesterase inhibitors

INVENTOR(S): Oota, Tomoki; Taguchi, Minoru; Kawashima, Yutaka; Hatayama, Katsuo

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF



DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08104679	A	19960423	JP 1995-175879	19950712
JP 3702493	B2	20051005		
PRIORITY APPLN. INFO.:			JP 1995-175879	A 19950712
			JP 1994-190388	19940812
OTHER SOURCE(S):		MARPAT 125:114672		
GI				



AB The title compds. I [R1 = H, Me, etc.; R2 = alkyl; n = 0 or 1; X = halo, etc.] are prepared The title compound II (NMR data given) in vitro showed IC50 of 2.9 nM against cyclic GMP phosphodiesterase.


IT 178937-86-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazoline derivs. as cyclic GMP phosphodiesterase inhibitors)

RN 178937-86-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]-4-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L4 ANSWER 143 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:241537 CAPLUS

DOCUMENT NUMBER: 124:289561

ORIGINAL REFERENCE NO.: 124:53702h,53703a

TITLE: Preparation of thienopyrimidinones as cyclic GMP phosphodiesterase inhibitors

INVENTOR(S): Oota, Tomoki; Kawashima, Yutaka; Hatayama, Katsuo

PATENT ASSIGNEE(S): Taisho Pharma Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07330777	A	19951219	JP 1994-126555	19940608
PRIORITY APPLN. INFO.:			JP 1994-126555	19940608
OTHER SOURCE(S):	MARPAT	124:289561		
GI				




AB The title compds. I [R1 = alkyl; n = 0 or 1; X = halo, cycloalkyl, etc.] are prepared I [X = morpholino; n = 0; R1 = ethyl] (preparation given) at 28 µg/Kg decreased blood pressure in rats by 15 mmHg.

IT 175595-30-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thienopyrimidinones as cyclic GMP phosphodiesterase inhibitors)

RN 175595-30-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-propoxy-3-(3,4,6,7-tetrahydro-4-oxothieno[3,2-d]pyrimidin-2-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L4 ANSWER 144 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:921905 CAPLUS

DOCUMENT NUMBER: 123:340203

ORIGINAL REFERENCE NO.: 123:61067a,61070a

TITLE: Preparation of thienotriazolodiazepines as inflammation inhibitors

INVENTOR(S): Moriwaki, Minoru; Kitani, Hiroyuki; Ebara, Hideji; Komatsu, Hiroshi; Nagasawa, Mariko

PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan; Mitsubishi Welpharma Co.

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
 CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07179471	A	19950718	JP 1994-279036	19941114
JP 3633008	B2	20050330		
PRIORITY APPLN. INFO.:			JP 1993-285328	A 19931115
OTHER SOURCE(S):	MARPAT	123:340203		

GI




AB The title compds. I [Ar = Ph, etc.; R1 - R3 = Me, etc.; R4, R5 = hydroxyalkyl, etc.; or R4 and R5 may together form a ring] are prepared In the oxazolone challenge test, the average weight increase of ears treated with oxazolone in mice dosed with I [Ar = 4-ClC6H4; R1 = R2 = R3 = methyl; NR4R5 = NH(CH2)2OH] (preparation given) at 10 mg/Kg/day orally for 8 days was 11.2 ± 0.8 mg, vs. 17.7 ± 0.5 mg for controls treated with oxazolone alone.

IT 170365-98-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thienotriazolodiazepines as inflammation inhibitors)

RN 170365-98-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-4-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

ACCESSION NUMBER: 1995:858623 CAPLUS
 DOCUMENT NUMBER: 123:256357
 ORIGINAL REFERENCE NO.: 123:45843a,45846a
 TITLE: Preparation of anthranilic acid amide derivative as cyclic guanosine monophosphate-phosphodiesterase inhibitors
 INVENTOR(S): Ozaki, Fumihiro; Ishibashi, Keiji; Ikuta, Hironori; Ishihara, Hiroki; Souda, Shigeru
 PATENT ASSIGNEE(S): Japan
 SOURCE: PCT Int. Appl., 204 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518097	A1	19950706	WO 1994-JP2262	19941227
W: AU, CA, CN, FI, HU, KR, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2155662	A1	19950706	CA 1994-2155662	19941227
AU 9512824	A	19950717	AU 1995-12824	19941227
AU 694465	B2	19980723		
EP 686625	A1	19951213	EP 1995-903999	19941227
EP 686625	B1	19990526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1118595	A	19960313	CN 1994-191311	19941227
JP 08188563	A	19960723	JP 1994-336920	19941227
JP 3837673	B2	20061025		
HU 74450	A2	19961230	HU 1995-2512	19941227
RU 2128644	C1	19990410	RU 1995-120194	19941227
AT 180468	T	19990615	AT 1995-903999	19941227
FI 9503968	A	19951019	FI 1995-3968	19950823
NO 9503305	A	19951025	NO 1995-3305	19950823
US 5716993	A	19980210	US 1995-507476	19950914
PRIORITY APPLN. INFO.:			JP 1993-347092	A 19931227
			JP 1994-299110	A 19941109
			WO 1994-JP2262	W 19941227
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 123:256357				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Anthranilamide derivs. [I; R1, R2, R3, R4 = H, halo, OH, (halo)alkyl, (halo)alkoxy, nitro, hydroxyalkyl, cyano, (CH2)pNR9R10, S(O)qR13, (un)protected CO2H, (un)substituted tetrazolyl, CONH2, pyrazolyl, or imidazolyl; or adjacent two substituents selected from R1 - R4 together with the C atoms bonded to them forms a ring; wherein R9, R10 = H, (halo)alkyl, arylalkyl, heteroarylalkyl, acyl, (un)protected CO2H; or NR9R10 forms a ring; p = 0, 1-6; R13 = H, (halo)alkyl; q = 0, 1-2; R5, R6 = H, halo, OH, cyano, (halo)alkyl, (halo)alkoxy; or R5 and R6 together with the C atoms bonded to them form cycloalkane, oxolane, 1,3-dioxolane, or 1,4-dioxane ring; W = N, CH; R7, R8 = H, (halo)alkyl; or R1 and R7 together with the C atoms bonded to them form a ring optionally containing other N, O, or S atom; A = H, (halo)alkyl, X(CH2)mZ; wherein X = CO, CS, CH2, SO2; Z = OH, (halo)alkoxy, cyano, halo, etc.; Y = O, S; n = 0, 1-6] or pharmacol. acceptable salts thereof are prepared These compds. are

useful for the treatment of ischemic heart disease, angina pectoris, hypertension, pulmonary hypertension, heart failure, and asthma. Thus, 2-nitro-5-chlorobenzoic acid was refluxed with SOCl₂ in benzene for 4 h and concentrated to give 2-nitro-5-chlorobenzoyl chloride which was amidated with piperonylamine in the presence of Et₃N in THF to give a benzamide (II; R = NO₂). This compound was reduced by Fe powder in a mixture of AcOH, H₂O, and MeOH under gentle refluxing to give, after concentration and treatment with concentrated HCl in EtOH, N-piperonylanthranilamide derivative II. HCl (R

= NH₂). An anthranilamide derivative (III) showed IC₅₀ of 0.4 nM against cyclic guanosine monophosphate-phosphodiesterase preparation from pig aorta.


IT 169044-75-1P 169044-76-2P 169044-78-4P
169044-79-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate for preparation of anthranilamide derivs. as cyclic guanosine monophosphate-phosphodiesterase inhibitors)


RN 169044-75-1 CAPLUS

CN Benzoic acid, 5-chloro-2-[[(4-hydroxy-1-piperidiny)carbonyl]amino]-, (4-methoxyphenyl)methyl ester (CA INDEX NAME)




RN 169044-76-2 CAPLUS

CN Benzoic acid, 5-cyano-2-[[(4-hydroxy-1-piperidiny)carbonyl]amino]-, (4-methoxyphenyl)methyl ester (CA INDEX NAME)




RN 169044-78-4 CAPLUS

CN Benzoic acid, 5-chloro-2-[[(4-hydroxy-1-piperidiny)carbonyl]amino]- (CA INDEX NAME)




RN 169044-79-5 CAPLUS


CN Benzoic acid, 5-cyano-2-[[(4-hydroxy-1-piperidiny)carbonyl]amino]- (CA INDEX NAME)





IT 169043-97-4P 169043-99-6P 169044-00-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of anthranilamide derivs. as cyclic guanosine monophosphate-phosphodiesterase inhibitors)
 RN 169043-97-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2-[[[1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-4-chlorophenyl]-4-hydroxy- (CA INDEX NAME)



RN 169043-99-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[4-chloro-2-[[[3-chloro-4-methoxyphenyl)methyl]amino]carbonyl]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 169044-00-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2-[[[3-chloro-4-methoxyphenyl)methyl]amino]carbonyl]-4-cyanophenyl]-4-hydroxy- (CA INDEX NAME)




OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS
RECORD (15 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 146 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1995:849158 CAPLUS
DOCUMENT NUMBER: 123:256522
ORIGINAL REFERENCE NO.: 123:45879a, 45882a
TITLE: Preparation of amide group-containing compounds as
antithrombotics
INVENTOR(S): Himmelsbach, Frank; Linz, Guenter; Pieper, Helmut;
Austel, Volkhard; Mueller, Thomas; Weisenberger,
Johannes; Guth, Brian
PATENT ASSIGNEE(S): Dr. Karl Thomae GmbH, Germany
SOURCE: Ger. Offen., 46 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4326344	A1	19950209	DE 1993-4326344	19930805
EP 638553	A1	19950215	EP 1994-111620	19940726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2129374	A1	19950206	CA 1994-2129374	19940803
JP 07179424	A	19950718	JP 1994-183292	19940804
PRIORITY APPLN. INFO.:			DE 1993-4326344	A 19930805
OTHER SOURCE(S):			CASREACT 123:256522; MARPAT 123:256522	

GI



AB R1Z1Z2ZZ3Z4R4 [R1 = (un)substituted (di)azacycloalkyl, pyridyl; R4 = CO2H,

alkoxycarbonyl, SO₂H, tetrazolyl, etc.; Z = CO₂Z⁵, Z⁵CO, Z⁵CONH, NHCOZ⁵, etc.; Z¹ = bond, alk(en)ylene, O, S, NH, etc.; Z² = (un)substituted phenylene, cycloalkylene, etc.; Z³ = alk(en)ylene, phenylene, etc.; Z⁴ = bond, OZ⁵, SO₂-2Z⁵, NHZ⁵, etc.; Z⁵ = alkylene] were prepared. Thus, quinuclidine was condensed with the ylide from 3-(Ph₃P+H₂C)C₆H₄CO₂Me Br- and the reduced and saponified product condensed with Me trans-4-aminocyclohexanecarboxylate to give title compound trans-I.HCl (R = Me, R₂ = 4-quinuclidinylethyl, R₃ = H). Trans-I.HCl (R = R₂ = H, R₃ = 4-quinuclidinylmethoxy) had IC₅₀ of 85nM against BIBU 52 binding at human thrombocytes in vitro.


IT 168890-89-9P 168890-90-2P 168890-91-3P
 168891-26-7P 168891-63-2P 168891-64-3P
 168891-65-4P 168891-71-2P 168891-76-7P
 168892-34-0P 168892-35-1P 168892-36-2P
 168892-38-4P 168892-41-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of amide group-containing compds. as antithrombotics)

RN 168890-89-9 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[(butylsulfonyl)amino]-4-[[[4-(4-piperidinylmethoxy)-1-piperidinyl]carbonyl]amino]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 168890-90-2 CAPLUS

CN Cyclohexanecarboxylic acid, 1-(acetylamino)-4-[[[4-(4-piperidinylmethoxy)-1-piperidinyl]carbonyl]amino]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 168890-91-3 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[4-(4-piperidinylmethoxy)-1-piperidinyl]carbonyl]amino]-, cis- (CA INDEX NAME)


Relative stereochemistry.



RN 168891-26-7 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-(butylsulfonyl)-5-[[[4-(4-piperidinylmethoxy)-1-piperidinyl]carbonyl]amino]-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 168891-63-2 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[(butylsulfonyl)amino]-4-[[[4-(4-piperidinylmethoxy)-1-piperidinyl]carbonyl]amino]-, methyl ester, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.





● HCl

RN 168891-64-3 CAPLUS

CN Cyclohexanecarboxylic acid, 1-(acetylamino)-4-[[[4-(4-piperidinylmethoxy)-1-piperidinyl]carbonyl]amino]-, methyl ester, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 168891-65-4 CAPLUS

CN Cyclohexanecarboxylic acid, 1-amino-4-[[[4-(4-piperidinylmethoxy)-1-piperidinyl]carbonyl]amino]-, methyl ester, dihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 168891-71-2 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-(butylsulfonyl)-5-[[[4-(4-piperidinylmethoxy)-1-piperidinyl]carbonyl]amino]-, methyl ester, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 168891-76-7 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[4-(4-piperidinylmethoxy)-1-piperidinyl]carbonyl]amino]-, methyl ester, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 168892-34-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[[[4-[(butylsulfonyl)amino]-4-(methoxycarbonyl)cyclohexyl]amino]carbonyl]-4-piperidinyl]oxy]methyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)



Relative stereochemistry.



RN 168892-35-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[1-[[[4-(acetylamino)-4-(methoxycarbonyl)cyclohexyl]amino]carbonyl]-4-piperidinyl]oxy]methyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 168892-36-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[1-[[[4-[(1,1-dimethylethoxy)carbonyl]amino]-4-(methoxycarbonyl)cyclohexyl]amino]carbonyl]-4-piperidinyl]oxy]methyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 168892-38-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[1-[[[1-(butylsulfonyl)-6-(methoxycarbonyl)-3-piperidinyl]amino]carbonyl]-4-piperidinyl]oxy]methyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 168892-41-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[1-[[[4-(methoxycarbonyl)cyclohexyl]amino]carbonyl]-4-piperidinyl]oxy]methyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L4 ANSWER 147 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1984:511953 CAPLUS
 DOCUMENT NUMBER: 101:111953
 ORIGINAL REFERENCE NO.: 101:17113a,17116a
 TITLE: Polyalkyl piperidines
 INVENTOR(S): Karrer, Friedrich
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G. , Switz.
 SOURCE: Eur. Pat. Appl., 29 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 108709	A2	19840516	EP 1983-810447	19831003

EP 108709 A3 19861008
 R: DE, FR, GB, IT
 US 4569997 A 19860211 US 1983-537134 19830929
 JP 60084268 A 19850513 JP 1983-189125 19831008
 PRIORITY APPLN. INFO.: CH 1982-5924 A 19821008
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 101:111953
 GI



AB Hindered amines are prepared by reaction of 2,2,6,6-tetramethylpiperidine derivs. with di- or triisocyanates at -20° to $+50^{\circ}$ in an inert solvent, and are useful as light stabilizers for polymers, especially binders for lacquers. Thus, 0.2 mol I [53463-86-8] was treated with 0.1 mol hexamethylene diisocyanate [822-06-0] in THF at $22-25^{\circ}$, stirred overnight, and worked up to give the carbamoyl compound (II) [91815-75-7] with m.p. $113-115^{\circ}$. A film (0.1-mm thick) prepared from polypropylene [9003-07-0] 100, octadecyl β -(3,5-di-tert-butyl-4-hydroxyphenyl)propionate 0.2, Ca stearate 0.1, and II 0.25 part could be photoirradiated for >3420 h before the CO extinction value at 5.85μ reached .apprx.0.3, a value at which a control film became brittle and which was reached in the control after 900 h.


IT 91815-72-4 91815-73-5
 RL: PEP (Physical, engineering or chemical process); PROC (Process)
 (light stabilizers, for polymers)
 RN 91815-72-4 CAPLUS
 CN 1-Piperidinecarboxamide, N,N'-(4-methyl-1,3-phenylene)bis[4-(benzoyloxy)-2,2,6,6-tetramethyl- (9CI) (CA INDEX NAME)




RN 91815-73-5 CAPLUS

CN Decanedioic acid, 1-[[[3-[[[4-[[1,10-dioxo-10-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]decyl]oxy]-2,2,6,6-tetramethyl-1-piperidinyl]carbonyl]amino]methyl]-3,5,5-trimethylcyclohexyl]amino]carbonyl]-2,2,6,6-tetramethyl-4-piperidinyl 2,2,6,6-tetramethyl-4-piperidinyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L4 ANSWER 148 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1984:193629 CAPLUS
 DOCUMENT NUMBER: 100:193629
 ORIGINAL REFERENCE NO.: 100:29443a,29446a
 TITLE: Polyalkylpiperidine derivatives containing isocyanate groups
 INVENTOR(S): Karrer, Freidrich
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G. , Switz.
 SOURCE: Eur. Pat. Appl., 38 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 94343	A1	19831116	EP 1983-810168	19830421
R: CH, DE, FR,	GB, IT, LI			
JP 58194862	A	19831112	JP 1983-74862	19830427
PRIORITY APPLN. INFO.:			CH 1982-2567	A 19820427
OTHER SOURCE(S):	MARPAT 100:193629			

GI



AB A diisocyanate such as 2,4-tolylene diisocyanate (I) [584-84-9], isophorone diisocyanate [4098-71-9], or OCN(CH₂)₆NCO [822-06-0] and a piperidine derivative containing 1 or 2 isocyanate-reactive groups, such as 1-acetyl-4-hydroxy-2,2,6,6-tetramethylpiperidine (II) [63941-51-5], 1-benzyl-4-hydroxy-2,2,6,6-tetramethylpiperidine [52185-71-4], 1,2,2,6,6-pentamethyl-4-(octylamino)piperidine [90075-87-9], 4-benzoyloxy-2,2,6,6-tetramethylpiperidine [26275-88-7], or 4-hydroxy-1-(2-hydroxyethyl)-2,2,6,6-tetramethylpiperidine [52722-86-8], are used to prepare isocyanate group-containing compds., such as compd. III [90075-88-0], which are useful as light stabilizers in polymers, especially in acrylic polymer coatings. The isocyanate groups react with functional groups of the polymers, preventing migration of the stabilizers. Thus, 34.8 g I in 100 mL THF was treated slowly at 50° with 100 mL THF containing 19.9 g II to give III.


IT 90075-85-7P 90075-86-8P

RL: PREP (Preparation)

(preparation of, as reactive light stabilizer for polymers)

RN 90075-85-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-(benzoyloxy)-N-(3-isocyanato-4-methylphenyl)-2,2,6,6-tetramethyl- (CA INDEX NAME)




RN 90075-86-8 CAPLUS

CN Decanedioic acid, 1,10-bis[1-[[[3-isocyanato-4-methylphenyl)amino]carbonyl]-2,2,6,6-tetramethyl-4-piperidinyl] ester (CA INDEX NAME)

PAGE 1-A






OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)


L4 ANSWER 149 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1983:595009 CAPLUS
 DOCUMENT NUMBER: 99:195009
 ORIGINAL REFERENCE NO.: 99:30027a,30030a
 TITLE: Benzodiazepines and medicines containing them
 INVENTOR(S): Cassal, Jean Marie; Fischli, Albert Eduard; Szente, Andre
 PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 32 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
EP 84357	A1	19830727	EP 1983-100295	19830114
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
CA 1202023	A1	19860318	CA 1982-416049	19821122
US 4474777	A	19841002	US 1982-450603	19821217
AU 8310313	A	19830728	AU 1983-10313	19830112
ZA 8300207	A	19831026	ZA 1983-207	19830112
IL 67675	A	19860131	IL 1983-67675	19830113
FI 8300134	A	19830720	FI 1983-134	19830114
JP 58124774	A	19830725	JP 1983-4318	19830117
HU 31150	A2	19840428	HU 1983-135	19830117
HU 191041	B	19861228		
DK 8300193	A	19830720	DK 1983-193	19830118
NO 8300161	A	19830720	NO 1983-161	19830118
			CH 1982-313	A 19820119

PRIORITY APPLN. INFO.:
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 99:195009
 GI



I



II

AB Title compds. I R = H, R1 = glucosyl, galactosyl, mannosyl, OH-substituted alkyl; RR1N = OH-substituted azetidino, piperidino, pyrrolidino; R2 = alkyl, R3 = H, Me; R4, R5 = halo) were prepared as inhibitors of cholesterol absorption. Thus, Z-L-Ala-OH (Z = PhCH2O2C) was treated with SOCl2 and then amidated with 2-amino-5-nitro-2'-chlorobenzophenone to give anilide II. II was Z-deblocked by HBr/HOAc and then cyclized to give (S)-5-(2-chlorophenyl)-1,3-dihydro-3-methyl-7-nitro-2H-1,4-benzodiazepin-2-one, which was converted in 6 steps to I (R = H, R1 = (HOCH2)3C, R2 = R3 = Me, R4 = Cl, R5 = Br) (III). In mice, 100 μ mol III/kg (oral) reduced intestinal absorption of cholesterol by 70%.


IT 87634-82-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 87634-82-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-bromo-5-(2-chlorophenyl)-2,3-dihydro-1,3-dimethyl-2-oxo-1H-1,4-benzodiazepin-7-yl]-4-hydroxy-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 150 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1979:557614 CAPLUS
DOCUMENT NUMBER: 91:157614
ORIGINAL REFERENCE NO.: 91:25437a,25440a
TITLE: Benzamidopiperidine derivatives
INVENTOR(S): Wiskott, Erik
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Switz.
SOURCE: Ger. Offen., 18 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent

LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2802812	A1	19790726	DE 1978-2802812	19780123
PRIORITY APPLN. INFO.: GI			DE 1978-2802812	19780123



AB The saluretic (no data) compds. I [R = H, acyl, (substituted) Bz; R1-R4 = H, C1-4 alkyl; R1R2 = C2-3 alkylene; R5 = halogen, CF3] and their salts were prepared. Thus, II reacted with 4,3-Cl(H2NSO2)C6H3COCl in CHCl3 to give I (R = R3 = R4 = H, R1 = R2 = Me, R5 = Cl).


IT 71581-87-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 71581-87-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[3-(aminosulfonyl)-4-chlorophenyl]-4-hydroxy-2,6-dimethyl-, (2 α ,4 α ,6 α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 151 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1979:22820 CAPLUS

DOCUMENT NUMBER: 90:22820

ORIGINAL REFERENCE NO.: 90:3763a,3766a

TITLE: 4-Acyloxypiperidine

INVENTOR(S): Nikles, Erwin; Karrer, Friedrich

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Ger. Offen., 25 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2805838	A1	19780831	DE 1978-2805838	19780211

DE 2805838	C2	19891207		
FR 2381754	A1	19780922	FR 1978-5071	19780222
FR 2381754	B1	19800516		
GB 1587779	A	19810408	GB 1978-7001	19780222
JP 53111077	A	19780928	JP 1978-19979	19780224
JP 01007985	B	19890210		
US 4344877	A	19820817	US 1981-224859	19810114

PRIORITY APPLN. INFO.:

	CH 1977-2309	A	19770224
	US 1978-880662	A1	19780223
	US 1979-92890	A1	19791109

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 90:22820
 GI




AB The piperidinol esters I (R = (substituted) C1-20 cyclo)aliphatic, aromatic, heterocyclic, or aliphatic group, (esterified) CO₂H, (substituted) CONH₂; R₁ = H, C1-8 alkyl; R₂ = (substituted) C1-30 (cyclo)aliphatic group, aralkyl, aryl; Z = 1-4-valent bicycloaliph. group; n = 1-4; m = 0-3; m + n = 1-4] were prepared for use as nondiscoloring stabilizers for synthetic materials, e.g., polyolefins, polyurethanes. Thus, the Diels-Alder adduct of cyclopentadiene and di-Me maleate reacted with LiNH₂ and 1-benzyl-2,2,6,6-tetramethyl-1-piperidinol in xylene solution to give I (R = PhCH₂, R₁ = H, Z = bicyclo[2.2.1]hept-5-ene-2,3-diyl, n = 2, m = 0; isomeric mixture).

IT 68548-28-7P 68548-29-8P 68548-30-1P
 68548-31-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 68548-28-7 CAPLUS


CN Bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid,
 bis[2,2,6,6-tetramethyl-1-[(phenylamino)carbonyl]-4-piperidinyl] ester,
 (endo,endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 68548-29-8 CAPLUS
 CN Bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid,
 bis[2,2,6,6-tetramethyl-1-[(phenylamino)carbonyl]-4-piperidinyl] ester,
 (exo,exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 68548-30-1 CAPLUS
 CN Bicyclo[2.2.1]heptane-2,3-dicarboxylic acid,
 bis[2,2,6,6-tetramethyl-1-[(phenylamino)carbonyl]-4-piperidinyl] ester,
 (endo,endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 68548-31-2 CAPLUS
 CN Bicyclo[2.2.1]heptane-2,3-dicarboxylic acid,
 bis[2,2,6,6-tetramethyl-1-[(phenylamino)carbonyl]-4-piperidinyl] ester,
 (exo,exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.





OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)

L4 ANSWER 152 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1978:597599 CAPLUS
 DOCUMENT NUMBER: 89:197599
 ORIGINAL REFERENCE NO.: 89:30723a,30726a
 TITLE: Amide derivatives of 3,4,5-trimethoxybenzene

INVENTOR(S): Joulle, Maurice; Maillard, Gabriel; Warolin,
Christian Jean Marie; Lakah, Lucien
PATENT ASSIGNEE(S): METABIO, Fr.
SOURCE: Ger. Offen., 36 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2801187	A1	19780720	DE 1978-2801187	19780112
PRIORITY APPLN. INFO.: GI			GB 1977-16055	A 19770114




AB Sixty-six title compds. I [NRR1 = (un)substituted alkyl- or alkenylamino, cycloalkylamino, aralkylamino, tetrahydrofurfurylamino, pyrrolidino, piperidino, homopiperidino, isoxazolidinyl, morpholino, thiamorpholino, piperazino, tetrahydroquinolyl- or -isoquinolyl, tetrahydrobenzoxazinyl, tetrahydropyranylmethylamino; Z = O, NR2 (R2 = H, PhCH2, morpholinoethyl); Z1 = CO, CONH, CO2, SO2; m, n = 0, 1, 2], useful as tranquilizers, anticonvulsants, or sedative potentiators (data tabulated), were prepared by 9 methods. Thus, 2,6-dimethylmorpholine was added to a stirred solution of 3,4,5-(MeO)3C6H2NCO in ether and the mixture refluxed with stirring 7 h to give 79% carbamoylmorpholine II.

IT 68060-95-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 68060-95-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L4 ANSWER 153 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1978:74324 CAPLUS

DOCUMENT NUMBER: 88:74324

ORIGINAL REFERENCE NO.: 88:11741a,11744a

TITLE: Psychoactive agents. IV. Synthesis and CNS depressant activity of some β -arylethyl- and β -styrylureas

AUTHOR(S): Arya, V. P.; David, J.; Grewal, R. S.

CORPORATE SOURCE: Ciba-Geigy Res. Cent., Bombay, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1977), 15B(7), 635-40



CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 88:74324

GI



AB Treatment of 3,4-RR₁C₆H₃CH₂CR₂R₃NH₂ (R = H, MeO; R₁ = H, MeO, Cl, F; R₂, R₃ = H, Me) with COCl₂ gave 3,4-RR₁C₆H₃CH₂CR₂R₃NCO, which reacted with 8-aza-1,4-dioxaspiro[4.5]decane to give the ureas I. Styrylureas II (R₄ = H, Cl, F) and (phenylcyclopropyl)ureas III [R₅ = Q-Q₃, 4-hydroxy-4-(4-fluorophenyl)piperidino, (hexahydroazepin-1-yl)amino, ClCH₂CH₂CH₂NH] were prepared similarly. (Arylethyl)ureas were prepared from 9-aza-3,3-dimethyl-1,5-dioxaspiro[5.5]undecane, 9-aza-1,4-dioxaspiro[4.5]decane, 1-azaspiro[4.5]decane and 3-azaspiro[5.5]undecane. The central nervous system (CNS) depressant and anticonvulsant activity of these compds. were reported.


IT 65535-75-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 65535-75-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-fluorophenyl)-4-hydroxy-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L4 ANSWER 154 OF 154 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1961:59492 CAPLUS

DOCUMENT NUMBER: 55:59492

ORIGINAL REFERENCE NO.: 55:11409a-i,11410a-i,11411a-b

TITLE: 4-Hydroxypipicolic acid from Acacia species, and its stereoisomers

AUTHOR(S): Clark-Lewis, J. W.; Mortimer, P. I.

CORPORATE SOURCE: Univ. Adelaide, S. Australia

SOURCE: Journal of the Chemical Society (1961) 189-201

CODEN: JCSOA9; ISSN: 0368-1769

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB The title compound was isolated on a preparative scale from Acacia oswaldii leaves and separated from the accompanying acids through the Et2O soluble N-nitroso derivative (I). Hydrolysis of I and separation on an ion exchange column

gave (-)-pipicolic acid (II) and the hydroxy acid, which was shown by unequivocal degradations to be (-)-trans-4-hydroxy-L-pipicolic acid (III). III was converted by stereospecific transformations into cis-4-hydroxy-L- (IV) and -D-pipicolic acid (V), so that 3 of the 4 optically active forms of 4-hydroxypipicolic acid were now available. A. oswaldii leaves (5.5 g.) extracted with alc. and chromatographed on sulfonated polystyrene gave 95 g. amino acids. The imino acids were extracted into Et2O as the N-nitroso derivs. The imino acids (46 g.) dissolved in 58 cc. refluxing H2O, the solution diluted with alc., and cooled gave 4-hydroxypipicolic acid. Purification gave 23 g. III, m. 285-6° (decomposition); II was obtained as the HCl salt, m. 256-8° (6.5 g. from 17.3 kg. leaves), [α]18D -10.5° (c 8, H2O). Separation of II and III was also achieved by selective elution from Zeo-Karb 225; III was eluted with 0.02-0.4N HCl, and II (and proline) with 0.4-0.8N acid. The mother liquors from III from 20 kg. leaves treated this way, and the column finally washed with 1.6N HCl gave 1.66 g. compound, m. 231-4° (decomposition), [α]24D 15° (c 1, H2O). Milled heartwood of A. excelsa (2094 g.) similarly worked up gave 4 g. III and 0.35 g. II. Similar extns. of other samples of A. excelsa heartwood gave 0.017-0.08% III and 0.001-0.01% II. III (0.01-0.03%) was also obtained from A. mollissima heartwood and sapwood. III isolated as described above was obtained as prisms, m. 294° (decomposition) (alc.), [α]20D -13° (c 1, H2O). III did not react with HIO4; the 1-(2,4-dinitrophenyl) derivative formed prisms, m. 183°; Cu salt, blue prisms, m. 229° (decomposition). III on paper chromatograms sprayed with ninhydrin and heated 5-10 min. at 100-10° gave a greyish green to brownish purple color. III 1-benzoyl derivative obtained in 60-70% yield m. 174°, [α]15D -54° (c 1, alc.). Benzoylation of III with excess BzCl did not yield the dibenzoate. Heating the 1-benzoyl derivative of III caused epimerization at the 2-C atom. p-MeC6H4SO2Cl (0.95

g.) in Me₂CO with 0.58 g. III gave 0.7 g.
(-)-trans-4-hydroxy-1-p-toluenesulfonyl-L-pipecolic acid, m. 162°
(EtOAc-C₆H₆), [α]_D¹⁹ -16° (c 1, alc.). PhNCO (0.6 g.) was
added slowly during 10 min. to 0.58 g. III in 4 cc. N NaOH, diphenylurea
precipitated, and the solution acidified to give 0.48 g.
(-)-trans-4-hydroxy-1-phenylcarbamoyl-L-pipecolic acid (VI), m.
181-97°, [α]_D²⁶ -24.5° (c 1, alc.). VI (1.49 g.) in
refluxing H₂O gave 1.05 g. (-)-trans-4'-hydroxy-3-
phenylpiperidino[1',2':1,5] hydantoin (VII), prisms, m. 204-5°,
[α]_D²³ -53° (c 1, alc.). VII (0.61 g.) dissolved in 4.63 cc.
N NaOH and the solution diluted gave [α]_D -17°, [α]_D
-40° (after 3 hrs.) and [α]_D -45.4° after 24 hrs. III
(0.725 g.) in 25 cc. 50% aqueous C₅H₅N adjusted to pH 10 with 1.4 cc. N NaOH,
1.2 cc. phenylisothiocyanate added, the mixture shaken, extracted with C₆H₆,

the

aqueous layer acidified, and the solid collected gave 0.56 g.
(-)-trans-3-phenyl-4'-phenylthiocarbamoyloxypiperidino[1',2':1,5]-2-
thiohydantoin, m. 213-14°(alc.), [α]_D²² -74° (c 0.2,
alc.). III (0.051 g.), 0.023 g. red P, and 1 cc. HI heated 6 hrs. at
145° in a sealed tube gave 0.0076 g. II. III (2 g.), 0.32 g. red
P, and 20 cc. HI heated 12 hrs. at 150° in 4 sealed tubes and the
solns. combined contained II and other components. The materials separated on
Zeo-Karb gave 0.22 g. II.HCl. III (0.02 g.), 0.007 g. red P, and 0.2 HI
was heated 12 hrs. at 145°, evaporated, the residue dissolved in H₂O,
and examined by paper chromatography; III was absent and the chromatogram
showed II and compds. that were apparently 4-iodopipecolic acids. In the
2nd experiment the reduction mixture treated with Ag₂CO₃, the solids removed,

and the

aqueous phase chromatographed showed the presence of 2-amino-4-pentenoic acid
(VIII) and baikiaian (IX). VIII gave a purple color with ninhydrin at
110-15° and IX gave a gray-green color with ninhydrin and a pink
color with isatin. III (0.02 g.) was heated 9 hrs. at 145° with
0.0035 g. red P, and 0.2 cc. HI, evaporated, the residue treated in H₂O with
Ag₂CO₃ and the Ag salts separated. Half the supernatant solution was

hydrogenated

over PtO₂ 3 hrs. and chromatograms showed the presence of 2-aminopentanoic
acid (norvaline), II, and a minor component. III (2 g.) in 8 cc. PhAc
heated 1.5 hrs. at 190°, diluted with Et₂O, and extracted with 2N HCl
gave 0.52 g. 4-hydroxypiperidine, m. 55-65°; dimorphic
1-p-toluenesulfonate, m. 114-15° or 123-4°. CrO₃ (8N) in
7.5 cc. aqueous H₂SO₄ added to 2.18 g. III in 150 cc. AcOH, left 1.5 hrs. at
20°, MeOH added, the next day the solution decanted, the solns. from 4
such reactions evaporated, diluted, and the components separated on Zeo-Karb

gave

β-alanine and II. The oxo acid fractions were combined and evaporated to
give 1.28 g. 4-oxo-L-pipecolic acid-HCl-H₂O (X), decomposing 203°,
[α]_D²¹ 3.8° (c 2, H₂O). The HCl salt (0.4 g.) eluted from a
Zeo-Karb 225 column with N NH₄OH gave 0.19 g. (-)-4-oxo-L-pipecolic acid,
prisms, decomposing 240°, [α]_D²³ -14.8° (c 1, H₂O).

β-Alanine fractions collected and evaporated gave 0.59 g. containing II,
converted into 0.27 g. of the phenylcarbamoyl derivs. Authentic
N-phenylcarbamoyl-β-alanine was obtained as blades, m. 173-4°
(H₂O). PhNCO (0.3 g.) added during 15 min. to 0.4 g. X in 8 cc. 0.5N
NaOH, and the filtrate acidified gave

4'-oxo-3-phenylpiperidino(1',2':1,5)hydantoin (XI), m. 187°. XI
(0.1 g.) in alc. showed mutarotation after 23 hrs. XI exhibited
[α]_D²³ -87° (c 0.366, alc.). X (2 g.) in 20 cc. H₂O at pH 9
treated 1 hr. at room temperature with 0.112 g. NaBH₄ and the product treated

on

Zeo-Karb 225 gave IV.H₂O, plates, m. 265° (decomposition), [α]_D²³
-17° (c 1.1, H₂O). IV.2H₂O m. 265° (decomposition); Cu salt,
blue plates, m. 245° (decomposition); N-(2,4-dinitrophenyl) derivative


(62%), prisms, m. 134° (aqueous alc.). BzCl (0.15 g.) added portionwise to 0.163 g. IV. H₂O in 3.2 cc. 0.7N NaOH, and the filtrate acidified gave, after 14 hrs. at 0°, 0.119 g. N-benzoyl derivative, blades, m. 104°, [α]_D²³ -39.5° (c 1, alc.). The same product was obtained when 2.2 equivs. BzCl were used. Me 4-chloropicolinate (3.43 g.) in PhCH₂OH treated portionwise with 1 g. Na in 30 cc. PhCH₂OH, the mixture refluxed 45 min., 50 cc. H₂O, 100 cc. Et₂O, and 50 cc. 2N HCl added, the mixture shaken, the Et₂O washed with dilute HCl, the acidic exts. combined, washed, and 50 cc. 5N NaOH added, and the mixture stored at 0° gave 3.65 g. Na 4-benzoyloxypicolinate. Acidification gave 2.4 g. 4-benzoyloxypicolinic acid (XII), prisms, m. 172° (alc.); 83% HCl.H₂O salt, m. 162°. The HCl salt heated at 200° gave a liquid distillate consisting of PhCH₂Cl and 0.15 g. 4-hydroxypicolinic acid (XIII), prisms, m. 258° (decomposition). Hydrogenation of 1 g. XII in 20 cc. 5N HCl at room temperature over PtO₂ during 29 hrs. gave 0.52 g. XIII, m. 255-8°. Hydrogenation was inhibited in 1.5N NH₃ but in AcOH at 65° hydrogenation gave II and III. XII (6.46 g.) in 50 cc. H₂O hydrogenated 24 hrs. at 105°/70 atmospheric over 0.285 g. PtO₂ and the acids isolated from the soluble mixture of 1.91 g. by paper chromatography gave after 24 hrs. bands of II and 4-hydroxypipicolic acids. The product (0.29 g.) in dilute HCl was concentrated to give 0.075 g. (±)-cis-4-hydroxypipicolic acid-HCl, prisms, m. 253-5° (decomposition). III (6 mg.) heated 9 hrs. at 145° in a sealed tube with 0.1 cc. N NaOH gave a mixture of cis and trans isomers; a trace of the epimer was similarly formed by heating in H₂O alone, but not in N HCl. The epimeric mixture of imino acids formed by heating 5 mg. III in 0.3 cc. saturated aqueous Ba(OH)₂ 12 hrs. at 155° in a sealed tube was compared with a number of compds. III 1-benzoyl derivative (2.49 g.) heated 5 min. at 200°, refluxed 6.5 hrs. with 100 cc. 6N HCl, BzOH removed, and the aqueous layer paper chromatographed showed the presence of cis and trans-4-hydroxy acids in equal amts. III (2.9 g.) refluxed 4 hrs. with 30 cc. AcOH and 10.2 cc. Ac₂O gave 1.1 g. (±)-1-acetyl-4-hydroxy-D-pipicolic lactone (XIV), plates, m. 148-9° (EtOAc), [α]_D²⁴ 181° (c 1, alc.). XIV (1 g.) refluxed 3 hrs. with 50 cc. 2N HCl gave 0.74 g. V. 2H₂O, m. 266-9° (decomposition), [α]_D²⁴ 17° (c 1, H₂O). II was obtained from A. excelsa heartwood in prisms, m. 273-5° (decomposition); HCl salt, [α]_D²² -10.5° (c 6, H₂O). N-Benzoyl-L-pipicolic acid crystallized as prisms, m. 133°, [α]_D²² -72° (c 1, alc.). 1-Phenylcarbamoyl-L-pipicolic acid (80%) formed prisms, m. 178°, [α]_D²⁰ -39°. Recrystn. from refluxing H₂O gave the optically inactive phenylhydantoin (XV), m. 159-60°. (±)-Pipicolic acid-HCl (m. 258-60°) was obtained in 91% yield by hydrogenation of 5 g. picolinic acid in 20 cc. 5N HCl over 0.2 g. PtO₂ 24 hrs. at 25 atmospheric/60°. This salt (0.66 g.) in 8 cc. N NaOH treated with 0.59 g. PhNCO gave 0.81 g. (±)-1-phenylcarbamoylpipicolic acid, m. 138° and 156-8°. Recrystn. after refluxing 1 hr. with H₂O gave XV. Et β-ethoxycarbonylaminopropionate (38.1 g.) and 34.4 g. Et fumarate were added successively to 350 cc. C₆H₆ and 4.6 g. Na (the temperature rose to b.p. during 45 min.) the mixture finally refluxed 0.5 hr., diluted with Et₂O, extracted with Et₂O, washed, the strongly acidic solution saturated with NaCl, extracted with EtOAc, washed, dried, and the solvent evaporated gave 53.5 g. oil. The oil dissolved in 10N HCl, evaporated, and the residue refluxed 4.5 hrs. with 150 cc. alc. saturated with HCl gave 24.2 g. Et 1-ethoxycarbonyl-3-oxopyrrolidine-2-ylacetate (XVI), b.p. 122-8°; semicarbazone, m. 124°; dimorphic 2,4-dinitrophenylhydrazones, orange plates, m. 112-13°, or prisms, m. 135°. NaBH₄ (0.38 g.) in 1 cc. H₂O added during 10 min. at 15° to 4.86 g. XVI gave after chromatography 0.51 g. 3-hydroxypyrrolidin-2-ylacetic acid-H₂O, prisms, m. 215-16° (decomposition); N-(2,4-dinitrophenyl) derivative, prisms, m. 205° (aqueous alc.). The imino acid was recovered after

treatment with HNO₂. The phenylcarbamoyl derivative lost the elements of H₂O to give the lactone, prisms, m. 168°. The lactone was recovered after heating 8 hrs. on a steam bath with 3N HCl.

IT 100616-43-1, Pipecolic acid, 4-hydroxy-1-phenylcarbamoyl-
(stereoisomers)

RN 100616-43-1 CAPLUS

CN 2-Piperidinecarboxylic acid, 4-hydroxy-1-[(phenylamino)carbonyl]- (CA
INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS
RECORD (16 CITINGS)

=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 13:15:00 ON 09 AUG 2010